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ABSTRACT 
Molecular Basis of Gene Dosage Sensitivity 
by 
JianpingChen 
Deviation of gene expression from normal levels has been associated with diseases. 
Both under- and overexpression of genes could lead to deleterious biological consequences. 
Dosage balance has been proposed to be a key issue of determining gene expression pheno-
type. Gene deletion or overexpression of any component in a protein complex produces ab-
normal phenotypes. As a result, interacting partners should be co-expressed to avoid dosage 
imbalance effects. The strength of transcriptional co-regulation of interacting partners is 
supposed to reflect gene dosage sensitivity. Although many cases of dosage imbalance 
effects have been reported, the molecular attributes determining dosage sensitivity remain 
unknown. This thesis uses a protein structure analysis protocol to explore the molecular 
basis of gene dosage sensitivity, and studies the post-transcriptional regulation of dosage 
sensitive genes. 
Solvent-exposed backbone hydrogen bond (SEBH or called as dehydron) provides a 
structure marker for protein interaction. Protein structure vulnerability, defined as the ra-
tio of SEBHs to the overall number of backbone hydrogen bonds, quantifies the extent to 
which protein relies on its binding partners to maintain structure integrity. Genes encoding 
vulnerable proteins need to be highly co-expressed with their interacting partners. Pro-
tein structure vulnerability may hence serves as a structure marker for dosage sensitivity. 
This hypothesis is examined through the integration of gene expression, protein structure 
and interaction data sets. Both gene co-expression and protein structure vulnerability are 
calculated for each interacting subunits from human and yeast complexes. It turns out 
that structure vulnerability quantifies dosage sensitivity for both temporal phases (yeast) 
and tissue-specific (human) patterns of mRNA expression, determining the extent of co-
expression similarity of binding partners. 
Highly dosage sensitive genes encode proteins which are vulnerable to water attack. 
They are subject to tight post-transcriptional regulation. In human, this extra regulation 
is achieved through extensive microRNA targeting of genes coding for extremely vulnera-
ble proteins. In yeast, on the other hand, our results imply that such a regulation is likely 
achieved through sequestration of the extremely vulnerable proteins into aggregated states. 
The 85 genes encoding extremely vulnerable proteins contain the five confirmed yeast pri-
ons. It has been proposed that yeast prion protein aggregation could produce multiple phe-
notypes important for cell survival in some particular circumstances. These results suggest 
that extremely vulnerable proteins resorting to aggregation to buffer the deleterious conse-
quences of dosage imbalance. However, a rigorous proof will require a structure-based inte-
gration of information drawn from the interactome, transcriptome and post-transcriptional 
regulome. 
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Chapter! 
Introduction 
Gene expression phenotype has attracted significant interest, due to the advent of high-
throughput techniques such as DNA microarray. These new techniques allow quantitative 
expression measurement of thousands of genes simultaneously. Expression profiling has 
been widely used to detect disease-related genes [1, 2]. Many studies have established 
a relationship between human diseases and specific changes in gene expression [3, 4]. 
Both under- and overexpression of genes could lead to deleterious biological consequences. 
Dosage balance has been proposed to be a key issue of determining gene expression phe-
notype [5]. Spatially or chemically isolated functional modules such as protein complexes 
are responsible for discrete functions. Therefore, gene deletion or overexpression of any 
component in a protein complex results in a dosage imbalance, which could lead to dis-
ease. According to the dosage balance theory, interacting partners should be co-expressed 
to avoid dosage imbalance effects, and the strength of transcriptional co-regulation of in-
teracting partners is supposed to reflect dosage sensitivity. 
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Although numerous dosage imbalance effects have been documented in a variety of 
species, the molecular attributes determining the magnitude of these deleterious effects (i. 
e., the dosage sensitivity) remain unknown. We tackle this problem exploiting a structure 
marker of protein interactions. This structural marker, can be identified by solvent-exposed 
backbone hydrogen bonds (SEBHs or dehydrons). SEBHs are backbone hydrogen bonds 
poorly protected by surrounding nonpolar side chains [6]. SEBHs are exposed to water 
attack, and hence are weakly bonded. However, they can be stabilized upon approach 
of nonpolar groups. SEBHs are enriched in protein binding interface, and become well 
wrapped upon protein association [7]. The number of SEBHs quantifies the extent of 
protein connectivity. The more SEBHs a protein possesses, the more interactive it becomes. 
In this sense, the number of SEBHs also marks the level of protein structure vulnerability. 
Proteins rich in SEBHs depend on their binding partners for structural integrity, and are 
hence structurally vulnerable. 
Vulnerable proteins rely on their binding partners to maintain structure integrity. Changes 
in relative expression levels of vulnerable proteins and their interacting partners are likely 
to induce dosage imbalance effects. According the dosage balance theory, genes encoding 
vulnerable proteins are sensitive to dosage changes. This thesis examines this prediction 
through the integration of gene expression, protein structure and interaction data sets. 
In Chapter 2, we give a brief description of gene dosage effects and dosage balance 
hypothesis. We first provide several examples of gene expression phenotypes. Then we 
describe dosage balance theory that has been proposed to explain gene dosage effects. 
In Chapter 3, we define protein structure vulnerability on the basis of solvent exposed 
backbone hydrogen bonds. To do this, we first give the statistical definition of this type of 
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hydrogen bonds. Then we discuss their important role of marking protein interactions. At 
last, we give the definition of protein structure vulnerability. 
In Chapter 4, we study gene dosage sensitivity from protein structure perspective. This 
chapter presents the main results of this thesis, structural marker introduced in Chapter 3 is 
related to gene co-expression. We show that vulnerability quantifies dosage sensitivity for 
both temporal phases (yeast) and tissue-specific (human) patterns of mRNA expression, 
determining the extent of co-expression similarity of binding partners. 
In Chapter 5, we discuss the post-transcriptional regulation of expression of genes en-
coding extremely vulnerable proteins. Gene expression is subject to regulation at the post-
transcriptional stage. Genes encoding extremely vulnerable proteins need to be under tight 
control to avoid gene dosage imbalance effects. This chapter discusses the differences of 
regulatory mechanisms in human and yeast. 
In Chapter 6, we verify the relationship between protein structure vulnerability and 
gene dosage sensitivity by examining the effect of protein structure vulnerability on gene 
duplication. According to our prediction, duplicates of genes encoding highly vulnerable 
proteins should be more likely to cause dosage imbalance and hence be less frequently to 
be retained in evolution. Therefore, genes encoding vulnerable proteins should have less 
paralogs than genes encoding proteins with good packing quality. This chapter presents 
some important results on this issue. 
In Chapter 7, we give conclusions and discuss future work. Structure vulnerability 
provides a molecular basis for gene dosage imbalance effects. Genes encoding extremely 
vulnerable proteins are subject to strong post-transcriptional regulation. In human, this 
extra regulation is achieved through extensive microRNA targeting of genes coding for 
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extremely vulnerable proteins. In yeast, on the other hand, our results imply that such a 
regulation is likely achieved through sequestration of the extremely vulnerable proteins into 
aggregated states. These results imply that protein aggregation can buffer the deleterious 
effects of dosage imbalances. This chapter will give a brief discussion about this topic and 
suggest future work needed to elucidate this puzzle. 
Chapter 2 
Gene Dosage Effect and Dosage Balance 
Hypothesis 
Gene expression is the process by which the genetic information encoded on DNA 
is transferred to protein or RNA. The genetic information is not always accurately trans-
ferred in the gene expression process. Deviation of gene expression from normal levels, i.e. 
under- or overexpression, can arise from genetic, environmental, developmental or random 
biological effects. Gene expression variation usually leads to new phenotypes. Reduced 
gene dosage produces haploinsufficient effect, while increased gene quantity also results 
in abnormal phenotype. This chapter gives a brief description of gene expression and gene 
dosage effects, and then discusses dosage balance theory that is proposed to explain gene 
dosage effects. 
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2.1 Gene expression 
Gene expression involves two major stages: transcription and translation. At first, DNA 
sequence is transcribed into a complementary nucleotide RNA strand called messenger 
RNA (mRNA). Then, the mRNA codon sequence is translated into a chain of amino acids 
that form a protein. 
Gene expression levels can be evaluated by measuring mRNA levels. There are several 
ways to detect mRNA expression levels. One traditional technique is northern blotting 
[8], a process in which a sample of RNA separated on an agarose gel is hybridized to a 
radio-labeled RNA probe that is complementary to the target sequence. Northern blotting 
quantifies mRNA levels by measuring band strength in an image of a gel, which may result 
in lower quality data. Despite its shortages, northern blotting is still often used due to some 
particular benefits it offers, such as the ability to discriminate alternately spliced transcripts. 
In contrast to traditional methods which measure mRNA levels individually, modern 
techniques perform expression profiling in which transcript levels for many genes are mea-
sured at once. DNA microarray technology is one widely used expression profiling tech-
nique [9]. This high-throughput technology consists of an arrayed series of thousands 
of microscopic spots of DNA oligonucleotides. Each spot contains picomoles of a spe-
cific DNA sequence used as probes to hybridize a target (a cDNA or cRNA sample) un-
der high-stringency conditions. Targets are usually fluorophore-labeled and quantified by 
fluorescence-based detection. The probes are attached to a solid surface by a covalent bond 
to a chemical matrix in standard microarrays (Figure 2.1). The solid surface is usually a 
chip made of glass or silicon, commonly referred to as gene chip. 
Figure 2.1: A microarray chip with approximately 40,000 probes. The upper left corner 
shows one enlarged part of the chip, (from WIKI) 
2.2 Gene dosage effect 
Gene dosage effect refers to the relationship between genotype and phenotype. Devi-
ation of gene dosage from the normal level can produce new phenotypes. Reduced gene 
dosage produces haploinsufficiency effect, and gene over-expression may also lead to dis-
eases. 
2.2.1 Haploinsufficiency 
Haploinsufficiency is one phenomenon arising from the total, or partial, lack of activity 
of one copy of gene at a diploid locus. The Single functional gene copy only produces half 
of the normal amount of the gene product, leads to an abnormal phenotype. 
Several cases of haploinsufficiency have been documented in man. Collagens IIA1 and 
VA1 participates in the formation of connective tissue. The assembly of collagen fibril 
involves an initiation of micro-fibrils through a helical cooperative mechanism. It has been 
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shown that type I collagen self-associates efficiently only if the concentration of the protein 
exceeds a threshold value [10]. Haploinsufficiency effect has also been seen in human 
elastin, another polymeric component of the connective tissue [11]. Its polymerization 
also involves a highly cooperative monomer->oligomer self-association process [12]. 
In additional to human, other species also exhibit haploinsufficiency effects. It is known 
that haploinsufficiency of protamins 1 or 2 results in fertility in mice. Protamine is a major 
DNA-binding protein in the nucleus of sperm in most vertebrates. They help to constrain 
the DNA into a small space less than 5% of a somatic cell nucleus. The protamine-DNA 
interaction is a highly cooperative process [13]. A decrease in the amount of protamine 
leads to disruption of sperm nuclear formation and abnormal sperm function [14]. 
The above cases involve genes encoding proteins that are synthesized and required in 
large amount. There are also many examples of transcription factors which regulate the 
expression of target genes and normally work close to a threshold. Haploinsufficiency of 
the Wilms' tumor gene-1 (WT1) contributes to male-to-female reversal [15], while hap-
loinsufficiency of Steroidogenic factor 1 (SF1) is associated with adrenal failure [16]. 
2.2.2 Increased gene dosage effect 
In additional to reduced gene dosage, increased gene expression also causes phenotypic 
consequences. PLP and PMP22 are two genes associated with myelin formation. The 
former encodes the proteolipid protein PLP of the central nervous system, and the later 
produces the peripheral myelin protein 22 (PMP22). Duplication of these two genes results 
in Pelizaeus-Merzbacher disease/spastic paraplegia type II and the type 1A Charcot-Marie 
Tooth syndrome respectively [17]. 
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There are more examples of increased gene dosage leading to a gain-of-function that 
produces new phenotypes. SRY-related HMG box 9 (SOX9) is an essential transcription 
factor in chondrogenesis [18]. HI of SOX9 causes anomalies and gonadal dysgenesis in 
a 46, XY background [19]. However, duplication of a genomic region containing SOX9 
is responsible for female to male sex reversal [20]. Another example is manifested by the 
constitutive over-expression of ID1, an inhibitor of the DNA binding capacity of bHLH 
proteins. The resulted phenotype resembles that of the null mutation for E2A, a factor 
involved in B cell development [21]. 
2.3 Dosage balance hypothesis 
Section 2.2 discusses dosage effects caused by reduced or increased gene dosage. In 
those cases, we consider the changes of absolute expression levels. However, the dosage 
balance has been proposed to be a key issue. Let us take a look at an example in the budding 
yeast. Mlclp is a light chain for the myosin Myo2p. Mlclp contributes to the structural 
stability of Myo2p, and displays haploinsufficiency. However, reduced amounts of Myo2p 
can suppress the haploinsufficiency exhibited by Mlclp. It is the relative excess of Myo2p 
that is more likely to be responsible for the "toxic effect". It is clear that the stoichiometric 
balance also plays an important role in determining phenotypic effects. 
2.3.1 Gene dosage balance in macromolecular complexes 
Veitia proposed that the subunits of a complex should be balanced to avoid dominant 
fitness defects [5]. Accordingly, both under- and overexpression of individual components 
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within a complex tend to lower fitness. Consider a complex consist of proteins A and B. 
An excess of A induces dosage imbalance and hence may be deleterious ([22]): A could 
form homodimers which may disrupt pathways, it could interfere with interaction between 
B and other proteins, it leads to irreversible AB binding with an abnormal function, or it 
could produce toxic precipitates. Another more complicated example is a trimer A-B-C, 
where B is a bridge. An increase in the amount of B may lead to the irreversible formation 
of subcomplexes AB and BC. Stoichiometric imbalances in macromolecular complexes, 
therefore, can be a source of dominant phenotype. 
The dosage balance theory proposes several predictions ([22]): "adaptations should 
tend to minimize the degree of imbalance, heterozygous deletions or over-expression of 
one subunit should be deleterious, the strength of transcriptional coregulation of subunits 
is expected to reflect dosage sensitivity, and an imbalance caused by halving (or increas-
ing) gene dosage in one gene will be rescued, at least in part, by reducing (or increasing) 
expression of the interacting partner." 
Rapid degradation of unassembled ribosomal subunits may be one case of the first 
prediction, while the fourth prediction is evidenced by the example of Mlclp and Myo2p 
mentioned above. 
The other twos have been supported by a phenotype and gene expression analysis of 
protein complex in yeast (Saccharomyces cerevisiae) [23]. Protein complex annotation was 
extracted from MIPS comprehensive Yeast Genome Database. Fitness effect was measured 
by the growth rates of heterozygous and homozygous diploid strains for single-gene dele-
tions in the yeast genome. Only essential genes were considered to minimize measurement 
biases. It was found that genes with low heterozygous fitness are more enriched for com-
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ponents in complexes. Dosage sensitive genes are at least twice more likely to encode 
proteins involved in complexes than dosage insensitive genes (Figure 2.2) [23]. On the 
other hand, components of protein complexes counts 47% of the genes whose overexpres-
sion in wild-type cell is lethal [23]. This is a highly significant excess as compared to genes 
whose overexpression has no detrimental effect on fitness. These two facts strongly sup-
port the second prediction stating that under- and overexpression of subunits of a complex 
can be deleterious. 
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Figure 2.2: Correlation between dosage sensitivity and proportion of genes in protein com-
plex. Dosage sensitive genes (low heterozygote fitness) have a higher percentage of genes 
encoding components in protein complex than dosage insensitive genes [23]. 
Papp et al. test the third prediction by examining co-expression of interacting gene 
pairs [23]. They found that the interacting pairs with high fitness deficiency are much more 
co-expressed than the others (Figure 2.3 [23]). Only 20% of the interacting pairs with low 
fitness deficiency (less than 5%) are co-expressed, while more than 80% of the subunit pairs 
with high fitness deficiency (more than 15%) show co-expression evidence [23]. Dosage 
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sensitivity is shown to affect the strength of transcriptional co-regulation of subunits. 
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Figure 2.3: Correlation between dosage sensitivity and frequency of co-expressed interact-
ing pairs. Dosage sensitive genes (low heterozygote fitness) are more co-expressed than 
dosage insensitive genes [23]. 
Another important work that Papp et al. has done is to study the co-evolution of protein 
subunits. According to the balance theory, single gene duplications of subcomponents 
induce dosage imbalance and hence can be harmful. Therefore, interacting pairs should 
either remain sole copies or undergo gene duplication in the same time. Consistently Papp 
et al. found a large excess of solo copy pairs and interacting pairs with the same number 
of paralogues [23]. They also noticed that genes involved in complexes rarely have many 
paralogues. 
There is more evidence showing the impact of dosage balance on gene duplication. 
Yang and colleagues demonstrated that the proportion of duplicated genes decreases with 
the size of protein complexes [24]. Duplication of subunits in large protein complex is more 
likely to cause dosage imbalance, since there is less chance of synchronous duplication of 
'!' 
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all components. Another evidence is the clustering of genes encoding subunits of stable 
complexes on the yeast chromosomes [25]. 
2.3.2 Gene dosage balance in informational pathways 
Dosage imbalance problems are not restricted to protein complexes, but also exist in 
signal transduction and genetic pathways [26]. One example is the mitogen-activated pro-
tein kinase (MAPK) signaling module. This signal pathway includes a phosphorylation 
cascade involving three main levels: MAPKKK, MAPKK and MAPK, along with their 
corresponding phosphatases (Figure 2.4). It is a Goldbeter-Koshland (GK) switch system 
[27], which responds to extracellular stimuli in a switch-like manner. When MAPKK and 
nuclear MAPK-phosphatase are saturated, the response of the system, represented by the 
quantity of MAPK's phosphorylated form (MAPK*), is dependent on the ratio of active 
MAPKK to MAPK-phosphatase. A sharp transition occurs in the signal-response curve, as 
the ratio exceed a critical value. A change in the ratio of MAPKK and MAPK-phosphatase 
leads to a shift in the response curve, and probably a fitness defect. On the contrary, the 
parallel change of both proteins, which keeps the ratio constant, does not alter the position 
of the threshold or the shape of the curve, as long as they are saturated. Another example 
is established in genetic circuits in which a dosage balance between repressors is required 
for bi-stability [26]. 
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Figure 2.4: Illustration of gene dosage balance in signaling pathways, (a) Schematic rep-
resentation of a mitogen-activated protein kinase (MAPK) pathway. The smaller rectangle 
represents a Goldbeter-Koshland (GK) switch [27]. (b) The response of the GK switch 
system as a function of the ratio of active MAPKK to MAPK-phosphatase. The blue line 
represents the normal response, while the pink and red lines represent the response for 
double the gene dosage of either MAPKK or MAPK-phosphatase respectively [26]. 
2.4 Summary 
Gene expression is a process of transferring information from DNA to proteins. Some-
times, genes are expressed in reduced or increased quantity. Both under- and overexpres-
sion of genes could produce abnormal phenotypes. Dosage balance has been proposed to 
be a key factor in determining gene expression phenotype. Stoichiometric imbalances in 
macromolecular complexes and informational pathways are a source of dominant pheno-
types. Protein subunits from the same complex should be co-expressed to avoid dosage 
imbalance effects. The strength of transcriptional co-regulation of interacting pairs is ex-
pected to reflect dosage sensitivity. Several experimental results have provided strong sup-
port to gene dosage theory. 
Chapter3 
Protein structure vulnerability 
This chapter describes a structure marker of protein interactivity referred to Solvent Ex-
posed Backbone Hydrogen bond (SEBH) or dehydron, and quantifies the extent of protein 
structure vulnerability based on this new structure feature. 
3.1 Solvent exposed backbone hydrogen bond 
Hydrogen bonding is one major component that determines the protein structure stabil-
ity. While most backbone hydrogen bonds are well protected, a few of them are exposed 
to solvent desolvation. These solvent exposed hydrogen bonds are under-wrapped, and 
vulnerable to water attack. 
15 
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3.1.1 An introduction to protein structure 
Proteins are building blocks of a living cell. They catalyze biochemical reactions. They 
are structural components of muscle, membranes and membrane channels. They also play 
an important role in immune responses, cell signaling and the cell cycle. The proper func-
tion of proteins demands an adoption of fairly rigid spatial structures. A minor shift in 
three-dimensional (3D) structures can lead a loss of or dramatic changes in protein activi-
ties. 
Proteins are polymers of amino acids. An amino acid is a molecule that contains both 
amine and carboxyl groups. The general formula for the amino acid is H2NCHRCOOH, 
where R stands for organic substitute. There are 20 common amino acids: alanine, arginine, 
asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, 
leucine, lysine, methionine, phenylalaine, proline, serine, threonine, tryptophan, tyrosine, 
and valine. The carboxyl group (-COOH) of one amino acid reacts with the amino group 
(—NH2) of another amino acid, which produces a molecule of water (H2O) and a peptide 
bond (CO-NH) (Figure 3.1). 
Amino acids can be classified as being hydrophilic or hydrophobic, according to the 
polarity of the side chain (Table 3.1). The physical properties of the side chains are impor-
tant in protein structure and protein-protein interactions. Nonpolar groups tend to cluster 
together to minimize the solvent exposure area and the entropy cost of forming hydrogen-
bond network. The clustering of nonpolar groups is referred as hydrophobic effects. On 
the contrary, polar groups interact with each other through hydrogen bonding or other in-
teractions. 
Polypeptides and proteins are chains of amino acids connected by peptide bonds. The 
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Amino acid (1)
 H Amino acid (2) 
Water 
Dipeptide 
Figure 3.1: Illustration of peptide bond formation (from WIKI). 
sequences of amino acids, which are encoded on DNA, determine the 3D structure of 
proteins. A protein sequence is called its primary structure. The primary structure is then 
folded to 3D structure, which is often composed of regular secondary structures, namely, 
a-helix and j3-sheet (Figure 3.2 (a), a-helix (red), /3-sheet (yellow)). The 3D structure of 
a single protein molecule is referred to tertiary structure. Complexation of several protein 
molecules produce a large protein complex regarded as the quaternary structure of a protein 
(Figure 3.2 (b)). The tertiary structure of the protein is determined by the distribution of 
hydrophilic and hydrophobic amino acids, and the quaternary structure is influenced by 
amino acids on protein surface. For example, soluble proteins' surfaces are often rich 
in polar amino acids like serine and threonine, while integral membrane proteins tend to 
place hydrophobic amino acids on their surface that helps them enter the lipid bilayer. 
Similarly, proteins binding to positively-charged molecules have many negatively charged 
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Table 3.1: 20 amino acids and their side chain properties (from WIKI). 
Amino Acid Side chain polarity Side chain acidity or basicity of neutral species 
Glycine 
Alanine 
Valine 
Leucine 
IsoLeucine 
Methionine 
Proline 
Phenylalanine 
Tyrosine 
Tryptophan 
Serine 
Threonine 
Cysteine 
Asparagine 
Glutamine 
Aspartate 
Glutamate 
Lysine 
Arginine 
Histidine 
nonpolar 
nonpolar 
nonpolar 
nonpolar 
nonpolar 
nonpolar 
nonpolar 
nonpolar 
nonpolar 
nonpolar 
polar 
polar 
polar 
polar 
polar 
polar 
polar 
polar 
polar 
polar 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
neutral 
acidic 
acidic 
basic 
basic(strongly) 
basic(weakly) 
amino acids on their surface, while proteins interacting with negatively-charged molecules 
have surfaces rich with positively charged chains. 
The folding of ploymers into 3D structures is driven by a number of noncovalent in-
teractions including hydrogen bonding, ionic interactions, Van der Waals forces, and hy-
drophobic packing. A hydrogen bond forms between an electronegative atom and a hy-
drogen atom bonded to nitrogen, oxygen or fluorine. Ionic interaction is the electrostatic 
interaction between metal and non-metal ions. Van der Waals force is the force between 
molecules which includes dipole-dipole force, instantaneous dipole-induced dipole force. 
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Figure 3.2: (a) The 3D structure of a single protein (PDB.2VEU). a-helix is colored as red, 
and j3-sheet is colored as yellow. (b)The 3D structure of a protein complex (PDB.1KB9). 
The cyan chain represents cytochrome b-cl complex subunit 1, and the blue chain repre-
sents Cytochrome c oxidase subunit 2. 
Hydrophobic interaction is the tendency of nonpolar components to form aggregates to 
minimize their contacts with water. In addition to protein folding, these interactions also 
contribute to the stability of protein structure. Among these interactions, hydrogen bond-
ing is a major component in stabilizing protein structure. A hydrogen bond is typically 5 
to 30 kJ/mol [28], comparable to that of weak covalent bonds (155 kJ/mol, [29]). Hydro-
gen bonds are often found in a-helices and j3-sheets as shown in Figure 3.3. They were 
attributed to a critical role in formation of a-helix and j8-sheet, when Pauling proposed the 
secondary structure model of protein [30, 31]. 
3.1.2 The wrapping of hydrogen bonds 
Protein folding involves burial of hydrophobic residues, which provide protection for 
hydrogen bonds from water attack. In proteins, most of the backbone hydrogen bonds 
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Figure 3.3: Backbone hydrogen bonds (shown as yellow bonds) in a-helix (a) and j3-
sheet (b) (PDB.1JAT). The cyan, blue and red balls represent covalent bonds contributed 
by carbon, nitrogen and oxygen atoms respectively. Graph was prepared using VMD. 
are well protected by the hydrophobic groups of the side chains. These kinds of hydro-
gen bonds have a high bonding energy and hence are essential for stabilizing the protein 
conformation. Both statistical and theoretical approaches have been employed to quantify 
the extent to which the hydrogen bonds are protected by proteins [6, 7, 32]. The results 
showed that about 92% of backbone hydrogen bonds were well protected and about 8% of 
hydrogen bonds are vulnerable to water attack [32]. Those under-wrapped hydrogen bonds 
are proposed to be central to protein-protein interaction [6, 7, 32]. They are termed as Sol-
vent Exposed Backbone Hydrogen bond (SEBH) or dehydron. When a hydrophobic group 
approaches to a dehydron, the water molecules around the dehydron are excluded and the 
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dehydron turn into a well wrapped hydrogen bond which has a high bonding energy. The 
net energy gain in this process has been experimentally determined to be close to 4kJ/mol 
[33], which is significant and comparable to the strength of hydrophobic interaction. 
The majority of backbone hydrogen bonds are well protected by the surrounding non-
polar groups. The level of wrapping could be quantified by counting the number of hy-
drophobic groups in the dehydration domain of the hydrogen bond. The dehydration do-
main is defined as two spheres of radius R centered at the alpha-carbons of the residues 
paired by the hydrogen bond (see Figure 3.4). This value of R is related to the character-
istic length A of the solvent-structuring effect due to the presence of a vicinal hydrophobe 
[34]. By fixing A at 1.8 A (the effective thickness of a single-layer water cavity) and as-
o 
suming structuring influence decays exponentially, R is set to be 6.0A (~ 3A) to reduce the 
structuring influence to 1% of its maximum value. The level of wrapping of the hydrogen 
bond p is measured by the number of hydrophobic groups in the domain. 
protein backbone 
Figure 3.4: Illustration of the dehydration domain of a hydrogen bond. As shown in this 
figure, the wrapping level of the hydrogen bond p = 15. 
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In structures of PDB-reported soluble proteins, at least two thirds of the backbone hy-
drogen bonds are protected on average by p = 26.6 ± 7.5 side-chain nonpolar groups for a 
desolvation ball radius 6 A. SEBHs are those hydrogen bonds whose p lies in the tails of 
the distribution, i.e. their microenvironment contains 19 or fewer nonpolar groups, so their 
p-value is below the mean (p = 26.6) minus one standard deviation (o" = 7.5). 
The nearly constant p value reflects the generic composition of the protein chains. On 
the other hand, the dispersion a is largely due to the variation of the size of the side chains. 
The large hydrophobic residues provide better protection for the hydrogen bond than small 
residues, and the number of large hydrophobic residues required to protect the hydrogen 
bond is less than that of small residues. No backbone hydrogen bond has less than two 
hydrophobic residues or more than eight in its desolvation domain [34]. 
3.1.3 Wrapping and disorder score 
SEBHs or dehydrons are hydrogen bonds whose wrapping levels are significantly lower 
than average hydrogen bonds. They are vulnerable to water attack. As a result, regions con-
taining dehydrons are supposed to be disordered to some extent. The relationship between 
wrapping and disorder is studied using the highly accurate disorder prediction program 
PONDR [35]. PONDR predicts structural disorder from sequence by quantifying sequence 
attributes over windows of 9 to 21 amino acids [36, 37, 38]. Those attributes including hy-
dropathy and sequence complexity are averaged over windows and the values are used to 
guide the prediction [37]. The predictor assigns a disorder score XD, ranging from 0 to 1, 
to each residues along the sequence. The disorder score XQ represents the propensity of the 
residue to be in a disordered region: Xp = 0, the residue absolutely belongs to an ordered 
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region; XD = 1, the residue is absolutely resided in a disordered region. There is 6% of false 
positive predictions of disorder in sequence windows of >= 40 amino acids for more than 
1, 100 nonhomologous PDB proteins. However, this value is overestimated due to the fact 
that many disordered regions in monomeric chains become ordered upon ligand binding or 
in crystal contacts. 
Disorder analysis has been performed over 2,806 nonredundant nonhomologous PDB 
domains, and the disorder score for each residue has been obtained. Residues were grouped 
to 45 bins (8<= p <= 52), according to the level of wrapping of hydrogen bonds in which 
these residue are engaged. Disorder scores were averaged over each group of residues. 
Figure 3.5 shows the correlation between disorder score at a particular residue site and 
the extent of wrapping of the hydrogen bond engaging that residue (if any). The strong 
correlation implies that regions rich in dehydrons tend to adopt a natively disordered state. 
The backbone hydrogen bonds need enough protection from other parts of protein and 
contribute to the stability of protein structures. 
The strong correlation between disorder score and the wrapping level of hydrogen 
bonds also enable us to predict the existence of dehydrons on the sequence basis. For 
regions with a disorder score XQ>0.35, the accuracy for dehydron prediction is 94%. De-
hydrons are a structural feature, and structures can not be obtained from sequence. It might 
be surprising that dehydrons can be inferred from sequence. However, PONDR employs 
a learning strategy that incorporates sequence windows in its training set together with the 
structural context in which such windows occur. The inclusion of structure information in 
disorder predictions provides the basis of high accuracy of predicting dehydrons. 
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Figure 3.5: Correlation between disorder score at a residue and the wrapping of the hydro-
gen bond in which the residue is engaged. 
3.2 Role of Dehydrons in protein interactions 
Dehydrons are identified as packing defects in protein structure. They are highly sen-
sitive to the water removal, and are important in protein association. Upon protein as-
sociation, dehydrons in the binding interface become dehydrated and stable, which then 
contribute to stability of protein structures. The number of dehydrons therefore serves as a 
quantifier of protein interactions. 
3.2.1 Dehydrons as a determinant of protein association 
As defined in the second method, dehydrons are those bonds whose Coulomb energy 
could change dramatically with the presence of a new hydrophobe from a binding partner. 
Therefore, dehydrons could serve as good indicator for binding sites. By examining the 
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protein-protein interface of 212 complexes from an exhaustive database, it is found that the 
density of dehydrons in the interface 8jnt is higher than the overall density of dehydrons 8: 
77 have 5int/8 > 1.5, some even has 7 times higher density of dehydrons in the interface. 
92.9% of the PDB complexes have higher density of dehydrons at the protein-protein inter-
face than the average density for individual monomelic partners [7]. The dehydrons in the 
interface of monomeric proteins become well wrapped in the complexes. The high density 
of dehydrons in the interface indicates that the exclusion of water from the structurally 
defective region play an important role in protein-protein association. 
3.2.2 Dehydrons as an indicator of protein interactivity 
As a strong indicator of protein interactivity, dehydrons could further provide insight 
into the pattern of proteomic connectivity. A systematic investigation of the dehydron and 
interaction patterns of all monomeric PDB domains from the yeast proteome found that 
domain connectivity is proportional to the average number of dehydrons in the family [39]. 
Figure 3.6 shows a correlation of the number of dehydrons in all monomeric PDB domains 
from the yeast proteome and the number of their interacting partners obtained from the 
Database of Interacting Proteins (DIP). 
The almost linear correlation between the number of dehydrons and the number of in-
teraction also holds for structural families (or Structural Classification of Proteins (SCOP) 
superfamilies) (see Figure 3.7 A) [39]. The numbers in the figure are the SCOP IDs for 
some protein domains. These two results suggest that the domain connectivity is measured 
by the average number of dehydrons < r > in a given family. Figure 3.7 B displays the 
distribution of protein families according to their < r >. The fraction / = / ( < r >) of 
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Figure 3.6: The number of dehydrons of a protein domain as a function of protein inter-
activity. The number of dehydrons of a given domain fold is obtained by averaging over 
all proteins in the domain, and protein interaction data are from Database of Interacting 
Proteins (DIP). The correlation is quite strong, with a correlation coefficient of 0.88 [39]. 
protein families follows the same power law / ( < r >) oc< r >~y as the distribution of 
protein connectivity, which further confirm the relationship between < r > and proteomic 
interactivity. The index y for H. sapiens, M.musculus and E. coli are respectively 1.44, 
1.49 and 2.1 [39]. 
3.3 Definition of protein structure vulnerability 
Proteins with large number of dehydrons are more likely to be involved in protein as-
sociation. Protection from their binding partners stabilizes dehydrons at binding interfaces 
by excluding water molecules in their microenvironment. The number of dehydrons there-
fore could measure the extent of protein structure vulnerability. The higher percentage of 
dehydrons a protein has, the more vulnerable this protein becomes. 
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Figure 3.7: (A) Correlation between the average percentage of dehydrons and the con-
nectivity v of SCOP families represented in the PDB. The numbers in the graph are the 
SCOP IDs. (B) Distribution of SCOP families according to their average number < r > of 
dehydrons per 100 hydrogen bonds. / = / ( < r >) is the fraction of families with < r > 
dehydrons. • - H.sapiens; A - M. musculus; Q - E. coli [39]. 
Protein structure vulnerability is defined as the ratio v of dehydrons or SEBHs to the 
total number of backbone hydrogen bonds. According to this definition, the most vulner-
able protein is the potassium channel scorpion toxin HSTX1 (v = 100%, see Figure 3.8). 
It is highly active on voltage-gated Kvl.3 potassium channels. This protein belongs to the 
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scorpion short toxin family, which essentially contains potassium channel blockers of 29 to 
39 amino acids and three disulfide bridges. These proteins are characterized by their high 
affinities and different specificities for several types of potassium channels. Furthermore, 
it has the particularity to possess a fourth disulfide bridge. HsTXl binds with a picomolar 
affinity to the Kv 1.3 channels [40]. 
Figure 3.8: The wrapping pattern of the toxin protein (PDB.1QUZ). The backbone is repre-
sented as virtual bonds (shown as blue segments) joining consecutive a carbon atoms (grey 
spheres), and the green segments represent solvent exposed backbone hydrogen bonds. 
The side chains with yellow spheres represent cystine residues which form four disulfide 
bridges [41]. 
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3.4 Summary 
Hydrogen bonding makes a major contribution to protein structure stability. Protein 
folds in such a way that most backbone hydrogen bonds are well wrapped. Those well-
wrapped hydrogen bonds are stable and essential for stabilizing protein conformation. On 
the contrary, some backbone hydrogen bonds are exposed to solvent desolvation, and are 
vulnerable to water attack. Those solvent exposed hydrogen backbone hydrogen bonds 
(SEBHs) or dehydrons can be stabilized upon protection by nonpolar residues from in-
teracting proteins. SEBHs serve as a structural marker of protein interactivity. Protein 
structural vulnerability is quantified by the ratio of SEBHs over the total number of back-
bone hydrogen bonds. Proteins rich in SEBHs are vulnerable to water attack, and rely on 
their interacting partners to maintain structural integrity. 
Chapter 4 
Protein structure vulnerability as dosage 
sensitivity quantifier 
Biology system consists of separate functional modules, which results from spatial or 
specificity isolation. Protein complex is a typical spatial defined module, whose compo-
nents interact in the same time to promote a specific function. Dosage imbalance between 
subunits of a protein complex has become a key issue of genetic dominance. Both under-
and overexpression of subcomponents can be deleterious. The strength of transcriptional 
co-regulation of interacting pairs is assumed to reflect the dosage sensitivity. On the other 
hand, we found that structure vulnerability quantifies the extent to which proteins rely on 
their binding partners to maintain their structure integrity. Highly under-wrapped protein 
is vulnerable to water attack, and is highly needy for protection from other proteins. There-
fore, vulnerability should provide a molecular basis for co-expression of binding partners, 
and hence for dosage sensitivity. This chapter examines this prediction, by integrating tran-
30 
31 
scriptomics, metabolomics, and proteomics data sets of human and yeast (Saccharomyces 
cerevisiae). 
4.1 Materials and Methods 
4.1.1 Expression data sources 
Gene expression levels are assessed by DNA microarray analysis. DNA microarray 
is a high-throughput technology which measures the mRNA levels of thousands of genes 
simultaneously. Human expression profiles were obtained from Novartis gene expression 
atlas [42]. This expression dataset contains an extensive collection of human characterized 
and uncharacterized genes. For each gene, there are expression data from 79 tissue sam-
ples. We discarded six cancer tissues: ColorectalAdenocarcinoma, leukemialymphoblas-
tic(molt4), lymphomaburkittsRaji, leukemiapromyelocytic, lymphomaburkittsDaudi, leukemi-
achronicmyelogenous (k562). Yeast expression data was obtained from the Saccharomyces 
Genome Database [43]. This data set contains mRNA expression levels during a transition 
from glucose fermentative to glycerol-based respiratory growth. 
4.1.2 Protein interaction data sets 
We compiled structure curated protein interaction datasets following steps of Gerstein 
et al. [44]. All proteins in the interaction data set are mapped to Pfam domains [45]. The 
Pfam domain interactions are annotated in iPfam [46], which employ structure information 
to define domain interactions. Two proteins were then considered to interact with each 
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other, when their respective domains or homologs of their respective domains were found 
in a complex with PDB-reported structure. We obtained curated yeast protein domain inter-
actions from the Structural Interaction Network (SIN) [44], and filtered them using recently 
published yeast protein complex data [47]. The human interaction data set was extracted 
from the protein complex list in MIPS/Mammalian Protein Complex Database (MPCDB) 
[48]. This database does not include data from high-throughput experiments, but only 
manually annotated mammalian protein complexes extracted from individual experiments 
described in the scientific literature. All interactions among components in complexes were 
then curated using Pfam and iPfam. 
4.1.3 Calculation of expression correlation 77 
We use the Pearson correlation coefficients of expression vectors to determine similar-
ity between expression profiles. For two expression vectors X and Y, the Pearson correla-
tion coefficient Corr(X, Y) is given by 
Corr(X,Y) = < ^ < ' ^ < / » > , (4.,) 
where x, y are generic coordinates in the vectors X and Y respectively, and < > indicates 
mean over the 73 normal tissues (human) [42] or over the 5 metabolic adaptation phases 
(yeast) [43]. The expression correlation for a protein-protein interaction is then normalized 
by the mean correlation over all gene pairs encoding for interacting domains. The normal-
ization is necessary for comparative analysis across species because different species have 
different mean expression correlations and hence the significance of a correlation is neces-
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sarily a relative attribute. Given its statistical nature, the denominator is nonzero for any 
species since in a statistical sense, protein pairs that interact are expected to be positively 
correlated in their expression. 
4.1.4 Calculation of vulnerability v and identification of SEBHs for 
soluble proteins 
The structural vulnerability v of a protein is measured as the ratio of number of SEHBs 
to the total number of backbone hydrogen bonds. Identification of SEBHs was performed 
as described in Chapter 3. In this work, we adopted 6A as the length of the desolvation ball 
radius. Analysis over all structures of PDB-reported soluble proteins showed that at least 
two thirds of the backbone hydrogen bonds are protected on average by p = 26.6 ± 7.5 
side-chain nonpolar groups. Thus, SEBHs lie in the tails of the distribution, i.e. their 
microenvironment contains 19 or fewer nonpolar groups, so their p-value is below the 
mean (p = 26.6) minus one standard deviation (a = 7.5). 
In cases where the protein structures were unavailable from the PDB, we generated 
atomic coordinates through homology threading using the program Modeller [49, 50, 51]. 
Modeller is a computer program that models 3D structures of proteins subject to spa-
tial constraints [51], and was adopted for homology and comparative protein structure 
modeling. The homology threading was performed by adopting known homolog struc-
i 
tures as templates. Yeast PDB homologs were obtained from the Saccharomyces Genome 
Database, and human PDB homologs were from Pfam. We generated the alignment of the 
target sequence to be modelled with the Pfam-homolog structure reported in PDB and the 
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program computes a model containing all non-hydrogen atoms. The input for the compu-
tation consists of the set of constraints applied to the spatial structure of the amino acid 
sequence to be modeled and the output is the 3D structure that best satisfies these con-
straints. The 3D model is obtained by optimization of a molecular probability density 
function with a variable target function procedure in Cartesian space that employs methods 
of conjugate gradients and molecular dynamics with simulated annealing. 
4.2 Results 
4.2.1 The protein complex containing the most correlated interacting 
pair 
We quantitatively examined the relation between structural vulnerability of a protein 
and the extent of co-expression of genes encoding for its binding partners. First, we 
took a look at the mitochondrial respiratory chain complex III (Figure 4.1) who con-
tains the most highly correlated interacting subunits (?] =3.61) among all interactions 
we examined in this work. This protein complex, which is located in the mitochondrial 
inner membrane, consists of four redox centers: cytochrome b/b6, cytochrome cl and 
a 2Fe-2S cluster. The two highly co-expressed partners are subunits 1 and 2 from cy-
tochrome b-cl complex (subunit 1: Gene/ORF=COR1/YBL045C, shown in red; subunit 
2: Gene/ORF=QCR2/YPR191W, blue). As we can see from Figure 4.1 (b), subunit 1 (red) 
is rich in SEBHs (v = 57%) and hence structurally vulnerable. The high structure vul-
nerability of subunit 1 (red, cf. Figure b) renders it highly needy to interact with other 
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subunits of the complex to maintain its structural integrity. The co-expression of subunits 
1 and 2 is to ensure the protection of vulnerable structure. Figure 4.1 (c) shows the mutual 
protections of preformed SEBHs in the two subunits along part of their association inter-
face (red: COR1 residues 42-119; blue: QCR2 residues 250-331). This intermolecular 
mutual "wrapping" of local weaknesses illustrates the fact that the association contributes 
to maintain structural integrity (Figure 4.1 (c)). 
4.2.2 Correlation between protein structure vulnerability and gene 
expression in yeast 
It is the more vulnerable protein that relies more on its partner to maintain structural in-
tegrity. Therefore, its structural vulnerability should be the driving force for co-expression 
of two genes. As it turns out, a tight correlation (R2 = 0.891) between the maximum v-
value and the expression correlation r\ is obtained and shown to hold for all interacting 
pairs within the illustrative yeast complexes (Figure 4.2 a). This correlation is then found 
to hold across all 1,354 pairs of interacting proteins in the yeast interactome with Pfam 
representation (Figure 4.2 b, c). 
4.2.3 Correlation between protein structure vulnerability and gene 
expression in human 
Structure vulnerability is not only an organizing factor for the metabolic-adaptation 
transcriptome but also steers the organization of tissue-based transcriptomes. This is re-
vealed by a similar comparative analysis of comprehensive gene expression and structure-
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filtered interaction data for human [42, 48]. Thus, a clear (T] — v)-correlation is apparent 
between the co-expression of 607 gene pairs and the maximum structure vulnerability for 
each pair of interacting domains encoded in the ORFs of the respective genes (Figure 4.3). 
The strong (T] — v)-correlation implies that the protection of a functionally competent 
protein structure drives co-expression of its binding partners to an extent that is determined 
by the structure vulnerability. According to the gene dosage balance hypothesis, the extent 
of co-expression of interacting pairs reflects gene dosage sensitivity [26]. Therefore, the 
establishment of protein structure vulnerability as an organizing factor in yeast and human 
transcriptomes provides strong support for our hypothesis that protein structure vulnerabil-
ity is the molecular basis of gene dosage sensitivity. 
4.2.4 Protein intrinsic disorder and transcriptome organization 
When an isolated protein fold is unable to protect solvent exposed hydrogen bonds from 
water attack, the protein structure becomes vulnerable and some regions are not in ordered 
state. This view of structural vulnerability is supported by a strong correlation between the 
degree of solvent exposure of intramolecular hydrogen bonds and the local propensity for 
structural disorder discussed in Chapter 3: In the absence of binding partners, the inability 
of a protein domain to exclude water intramolecularly from pre-formed hydrogen bonds 
may be causative of a loss of structural integrity, and this tendency is marked by the disorder 
propensity of the domain [35]. These findings lead us to regard the predicted extent of 
disorder in a protein domain as a likely surrogate for its vulnerability and contrast it with 
the extent of expression correlation of its interactive partners. 
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As described in Chapter 3, the disorder propensity is determined by the disorder score 
fd (fd = 1. certainty of disorder; fd = 0, certainty of order) generated by PONDR-VSL2 
[36, 37, 38]. The extent of intrinsic disorder of a domain was defined as the percentage of 
residues predicted to be disordered relative to a predetermined fd - threshold (fd = 0.5). 
Reexamination of the expression correlations in the yeast and human transcriptomes 
was carried out taking into account a proteome-wide sequence-based attribution of the ex-
tent of disorder (% residues predicted to be disordered, or "disorder content") in interacting 
protein domains. The correlation results are shown in Figure 4.4. Although not strong, T]-
disorder correlations are still significant. The rj -disorder correlation coefficient is high 
for yeast (R2=OJ52) (Figure 4.4 a), implying that disorder content determines degree of 
coexpression of binding partners to a significant extent. We should also notice that the 
large dispersion in disorder extent at high levels of coexpression (45% dispersion versus 
15% for proteins with low disorder/low expression correlation). This fact indicates that 
highly disordered regions may adopt structures with very different levels of vulnerability 
depending on the complex in which they are involved. Therefore, the high dispersion to 
the r\ -disorder correlation reflects the nonlinear relationship between disorder extent and 
structure vulnerability. 
The T]-disorder correlation in human is considerably weaker (/?2=0.304, Figure 4.4 b) 
than in yeast. This is partly due to the fact that human proteins have a higher degree of 
disorder propensity than their yeast orthologs [35] and hence they are capable of signifi-
cantly diversifying their structural adaptation (induced folding) in different complexes. In 
this context, the extent of disorder becomes a poor surrogate of structural vulnerability, as 
different v-values may correspond to a single disorder prediction result. 
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The weaker r\ -disorder correlations is due to the fact that disorder score prediction 
is sequence-based. The disorder predictions did not include any structural information 
on induced fits arising upon complexation, and hence, unlike structure vulnerability, the 
predicted disorder score is independent of the complex under consideration. This fact in-
troduces deviations in the estimation of vulnerability through disorder content for proteins 
with extensive disorder content since their conformational plasticity may enable diverse 
induced-fit conformations with different vulnerabilities. 
4.3 Summary 
Protein structure vulnerability quantifies the extent to which protein relies on its bind-
ing partner to maintain structural integrity. Interacting pairs containing vulnerable proteins 
are more co-expressed than the other interacting pairs. The strong correlation between 
co-expression and maximum structure vulnerability of interacting pairs supports our pre-
diction that protein structure vulnerability quantifies the extent of gene dosage sensitivity. 
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Figure 4.1: Mutual protections of SEBHs in the two subunits of mitochondrial respiratory 
chain complex III. (a) Ribbon representation of mitochondrial respiratory chain complex 
III (PDB. 1KB9, [52]). (b) SEBH pattern for subunit 1 (red) and subunit 2 (blue). The 
interacting pair is characterized by a very high expression correlation r\ =3.61. The yel-
low square highlights the part of the interface shown in detail in (c). (c) Illustration of 
mutual protections of SEBHs in the two subunits along part of their interface. One side-
chain bond (between a and /3 carbon) is displayed. The thin blue lines, which connect 
J3 -carbons in one protein with centers of hydrogen bonds in the other protein, represent 
mutual protections of hydrogen bonds across the protein-association interface. Thus, a thin 
line is shown whenever the side chain of one protein is contributing with nonpolar groups 
to the microenvironment of a preformed hydrogen bond in its binding partner. 
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Figure 4.2: (a) Correlation between maximum structure vulnerability v and co-expression 
similarity r) for interactions within specific yeast complexes, (b) (rj — v)-correlation for 
all Pfam-filtered yeast protein interactions. Red points represent interactions involving 
extremely vulnerable proteins, (c) (17 — v)-correlation of Pfam-filtered yeast protein inter-
actions involving only PDB-reported proteins. The red data point represents an interaction 
involving an extremely vulnerable protein, and the green point represents an interaction 
involving a prion protein (ERF2, [53]). 
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Figure 4.3: (T] — v)-correlation for human protein interactions, (a) The (17 — v)-correlation 
for all Pfam-filtered human protein interactions. Red points represent interactions involv-
ing extremely vulnerable proteins that will be discussed in Chapter 5. (b) The correlation 
over Pfam-filtered human protein interactions that involve only PDB-reported proteins. 
The red point represents interaction containing an extremely vulnerable protein. 
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Figure 4.4: rj-disorder correlation for yeast (a) and human (b) protein interactions. The 
disorder content is quantified by the percentage of predicted disordered residues. 
Chapter 5 
Post-transcriptional regulation of 
expression of genes encoding extremely 
vulnerable proteins 
Messenger RNAs (mRNAs) are subjected to post-transcriptional regulation, after they 
are made from DNA. Gene expression may be repressed or silenced during post-transcriptional 
regulation. microRNAs (miRNAs) are a important class of post-transcriptional regulators. 
They regulate mRNA expression through two mechanisms: mRNA cleavage or transla-
tional repression. Genes encoding extremely vulnerable proteins are sensitive to dosage 
imbalance effects. Their expression should be tightly controlled by post-transcriptional 
regulators. This chapter discusses post-transcriptional regulation of genes encoding ex-
tremely vulnerable proteins in human and yeast. 
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5.1 Extremely vulnerable proteins 
The ( 7] — v )-correlations for human interactions are weaker than correlations for yeast 
interacting pairs. There are a few but significant outlier pairs (Figure 4.3, red data points) 
beyond the confidence band defined by a width of two Gaussian dispersions from the linear 
(77 — v)-fit. An examination of proteins sequences revealed that those outliers involve pro-
teins containing regions rich with poor protectors of backbone hydrogen bonds including 
gluatamine (Q) and asparagine (N). Regions rich with poor protectors could not adopt 3D 
structures, because they do not provide enough protection for backbone hydrogen bonds. 
Proteins with those regions are extremely vulnerable. They are prone to aggregate and 
form fibrils. Protein aggregation could lead to a loss-of-function and cause diseases. This 
is manifested by the Q-rich Huntington protein whose aggregation results in neurodegen-
erative disorder referred to Huntington disease. 
A census of regions rich with poor protectors was performed, and 115 proteins were 
found to contain those regions (Table 5.1). In addition to Q and N, we also took into 
account other residues: G, A, S, Y, and P. These poor protectors possess side chains with 
insufficient nonpolar groups, with polar groups too close to the backbone (thus precluding 
hydrogen-bond protection through clustering of nonpolar groups) [39] or with amphiphilic 
aggregation-nucleating character (Y) [53, 54, 55]. Charged backbone de-protecting side 
chains (D, E) are excluded since they would entail negative design relative to protein self-
aggregation. The (poor protector)-rich region spans 30 amino acids. This value was chosen 
to be consistent with the threshold used in a census of Q/N-rich regions [56]. In principle, 
a sizable window of residues unable to protect backbone hydrogen bonds produces a poor 
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folder, yielding a highly vulnerable structure [39, 57]. Thus, these sequences are either 
probably unable to sustain a stable soluble structure, or prone to relinquish the folding 
information encoded in the amino acid sequence in favor of self-aggregation [57]. 
Table 5.1: List of extremely vulnerable proteins in human 
Gene Symbol Entrez Gene ID SwissProt ID Protein Name 
HRNR 
ARID1B 
ARID 1A 
RBM14 
FUS 
ILF3 
EP400 
COL3A1 
HNRPUL1 
KHSRP 
MN1 
KRT9 
KRT10 
TAF4 
PEF1 
RANBP9 
MED15 
MAML3 
MED12 
TAF15 
TFG 
MAML2 
SAMD1 
ZFHX3 
SS18 
EWSR1 
388697 
57492 
8289 
10432 
2521 
3609 
57634 
1281 
11100 
8570 
4330 
3857 
3858 
6874 
553115 
10048 
51586 
55534 
9968 
8148 
10342 
84441 
90378 
463 
6760 
2130 
Q86YZ3 
Q8NFD5 
014497 
Q96PK6 
P35637 
Q12906 
Q96L91 
P02461 
Q9BUJ2 
Q92945 
Q10571 
P35527 
P13645 
000268 
Q9UBV8 
Q96S59 
Q96RN5 
Q96JK9 
Q93074 
Q92804 
Q92734 
Q8IZL2 
Q6SPF0 
Q15911 
Q15532 
Q01844 
Hornerin 
AT-rich interactive domain-containing protein IB 
AT-rich interactive domain-containing protein 1A 
RNA-binding protein 14 
RNA-binding protein FUS 
Interleukin enhancer-binding factor 3 
ElA-binding protein p400 
Collagen alpha-1 (III) chain precursor 
Heterogeneous nuclear ribonucleoprotein U-like protein 1 
Far upstream element-binding protein 2 
Probable tumor suppressor protein MN1 
Keratin, type I cytoskeletal 9 
Keratin, type I cytoskeletal 10 
Transcription initiation factor TFIID subunit 4 
Peflin 
Ran-binding protein 9 
Positive cofactor 2 glutamine/Q-rich-associated protein 
Mastermind-like protein 3 
Mediator of RNA polymerase II transcription subunit 12 
TATA-binding protein-associated factor 2N 
Protein TFG 
Mastermind-like protein 2 
Atherin 
Alpha-fetoprotein enhancer-binding protein 
SSXT protein 
RNA-binding protein EWS 
Continued on next page 
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Table 5.1: List of extremely vulnerable proteins in human 
Gene Symbol Entrez Gene ID SwissProt ID Protein Name 
ANXA11 
LOR 
HNRPA2B1 
POU3F3 
ANXA7 
LGALS3 
KRT1 
ZIC2 
FOXD2 
SHANK1 
SRRM2 
NOVA2 
COL17A1 
PRR12 
ZMIZ1 
HCN2 
DACH1 
KCNN3 
HECA 
ZSWIM5 
BMP2K 
FZD8 
WDR33 
HNRPAB 
ATXN2 
PHOX2B 
FUBP1 
MYST3 
PHLDA1 
PDCD6IP 
ZNF384 
311 
4014 
3181 
5455 
310 
3958 
3848 
7546 
2306 
50944 
23524 
4858 
1308 
57479 
57178 
610 
1602 
3782 
51696 
57643 
55589 
8325 
55339 
3182 
6311 
8929 
8880 
7994 
22822 
10015 
171017 
P50995 
P23490 
P22626 
P20264 
P20073 
P17931 
P04264 
095409 
060548 
Q9Y566 
Q9UQ35 
Q9UNW9 
Q9UMD9 
Q9ULL5 
Q9ULJ6 
Q9UL51 
Q9UI36 
Q9UGI6 
Q9UBI9 
Q9P217 
Q9NSY1 
Q9H461 
Q9C0J8 
Q99729 
Q99700 
Q99453 
Q96AE4 
Q92794 
Q8WV24 
Q8WUM4 
Q8TF68 
AnnexinAll 
Loricrin 
Heterogeneous nuclear ribonucleoproteins A2/B1 
POU domain, class 3, transcription factor 3 
Annexin A7 
Galectin-3 
Keratin, type II cytoskeletal 1 
Zinc finger protein ZIC 2 
Forkhead box protein D2 
SH3 and multiple ankyrin repeat domains protein 1 
Serine/arginine repetitive matrix protein 2 
RNA-binding protein Nova-2 
Collagen alpha-l(XVII) chain 
Proline-rich protein 12 
Zinc finger MIZ domain-containing protein 1 
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 
Dachshund homolog 1 
Small conductance calcium-activated potassium channel protein 3 
Headcase protein homolog 
Zinc finger SWIM domain-containing protein 5 
BMP-2-inducible protein kinase 
Frizzled-8 precursor 
WD repeat protein 33 
Heterogeneous nuclear ribonucleoprotein A/B 
Ataxin-2 
Paired mesoderm homeobox protein 2B 
Far upstream element-binding protein 1 
Histone acetyltransferase MYST3 
Pleckstrin homology-like domain family A member 1 
Programmed cell death 6-interacting protein 
Zinc finger protein 384 
Continued on next page 
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Table 5.1: List of extremely vulnerable proteins in human 
Gene Symbol Entrez Gene ID SwissProt ID Protein Name 
NKX2-3 
C14orf32 
ENAH 
SP8 
MED13L 
AMOT 
TRIM71 
FOXD1 
ATXN8 
SF1 
CDSN 
SUZ12 
NCOA6 
HNRPD 
HNRPAO 
SOX4 
EVX2 
MLL 
POU4F1 
NKX6-1 
POU6F2 
FOXL2 
ATN1 
HNRPA3 
SMARCA2 
VASP 
GSK3A 
YLPM1 
HD 
COL18A1 
KRT2 
159296 
93487 
55740 
221833 
23389 
154796 
131405 
2297 
724066 
7536 
1041 
23512 
23054 
3184 
10949 
6659 
344191 
4297 
5457 
4825 
11281 
668 
1822 
220988 
6595 
7408 
2931 
56252 
3064 
80781 
3849 
Q8TAU0 
Q8NDC0 
Q8N8S7 
Q8IXZ3 
Q71F56 
Q4VCS5 
Q2Q1W2 
Q16676 
Q156A1 
Q15637 
Q15517 
Q15022 
Q14686 
Q14103 
Q13151 
Q06945 
Q03828 
Q03164 
Q01851 
P78426 
P78424 
P58012 
P54259 
P51991 
P51531 
P50552 
P49840 
P49750 
P42858 
P39060 
P35908 
Homeobox protein Nkx-2.3 
Uncharacterized protein C14orf32 
Protein enabled homolog 
Transcription factor Sp8 
Thyroid hormone receptor-associated protein 2 
Angiomotin 
Tripartite motif-containing protein 71 
Forkhead box protein Dl 
Ataxin-8 
Splicing factor 1 
Corneodesmosin precursor 
Polycomb protein SUZ12 
Nuclear receptor coactivator 6 
Heterogeneous nuclear ribonucleoprotein DO 
Heterogeneous nuclear ribonucleoprotein A0 
Transcription factor SOX-4 
Homeobox even-skipped homolog protein 2 
Zinc finger protein HRX 
POU domain, class 4, transcription factor 1 
Homeobox protein Nkx-6.1 
POU domain, class 6, transcription factor 2 
Forkhead box protein L2 
Atrophin-1 
Heterogeneous nuclear ribonucleoprotein A3 
Probable global transcription activator SNF2L2 
Vasodilator-stimulated phosphoprotein 
Glycogen synthase kinase-3 alpha 
YLP motif-containing protein 1 
Huntingtin 
Collagen alpha-1 (XVIII) chain precursor 
Keratin, type II cytoskeletal 2 epidermal 
Continued on next page 
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Gene Symbol Entrez Gene ID SwissProt ID Protein Name 
OTX1 
HOXA13 
POLR2A 
SFPQ 
RFX1 
COL5A1 
POU3F2 
EGR1 
AR 
HNRPA1 
SYP 
COL2A1 
COL1A1 
FMNL1 
SS18L1 
LDB3 
BRD4 
PHLPP 
WIPF1 
HOXA3 
SETD1A 
SYN3 
HGS 
TCERG1 
SOX1 
WASL 
FOXE1 
5013 
3209 
5430 
6421 
5989 
1289 
5454 
1958 
367 
3178 
6855 
1280 
1277 
752 
26039 
11155 
23476 
23239 
7456 
3200 
9739 
8224 
9146 
10915 
6656 
8976 
2304 
P32242 
P31271 
P24928 
P23246 
P22670 
P20908 
P20265 
P18146 
P10275 
P09651 
P08247 
P02458 
P02452 
095466 
075177 
075112 
060885 
060346 
043516 
043365 
015047 
014994 
014964 
014776 
000570 
000401 
000358 
Homeobox protein OTX1 
Homeobox protein Hox-A13 
DNA-directed RNA polymerase II largest subunit 
Splicing factor, proline- and glutamine-rich 
MHC class II regulatory factor RFX1 
Collagen alpha-1(V) chain precursor 
POU domain, class 3, transcription factor 2 
Early growth response protein 1 
Androgen receptor 
Heterogeneous nuclear ribonucleoprotein Al 
Synaptophysin 
Collagen alpha-1 (II) chain precursor 
Collagen alpha-1(1) chain precursor 
Formin-like protein 1 
SS18-like protein 1 
LIM domain-binding protein 3 
Bromodomain-containing protein 4 
PH domain leucine-rich repeat-containing protein phosphatase 
WAS/WASL interacting protein family member 1 
Homeobox protein Hox-A3 
Histone-lysine N-methyltransferase, H3 lysine-4 specific SET1 
Synapsin-3 
Hepatocyte growth factor-regulated tyrosine kinase substrate 
Transcription elongation regulator 1 
SOX-1 protein 
Neural Wiskott-Aldrich syndrome protein 
Forkhead box protein El 
All outlier interactions in the human (77 — v)-correlation involve genes with extreme 
vulnerability (Figure 4.3 and Table 5.1). The (77 — v)-correlation reported in Figure 4.3 for 
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human is weaker than the yeast counterpart likely because, in contrast with yeast, mRNA 
levels are not a reliable surrogate for protein expression levels in human. Expression of hu-
man genes is subject to post-transcriptional regulation, and those genes encoding extremely 
vulnerable proteins should be under tight regulation. Recently, microRNA-mediated gene 
regulation has emerged as an important mechanism of post-transcriptional regulation. Here 
we study the post-transcriptional regulation of human genes encoding extremely vulnerable 
proteins by examining their microRNA targeting. 
5.2 microRNA 
microRNAs (miRNAs) are a novel class of non-protein coding RNAs that serve as post-
transcriptional gene regulators in a wide variety of organisms [58, 59]. These endogenous 
22 nucleotide RNAs negatively regulate gene expression by base-pairing with the 3' un-
translated regions (3' UTRs) of target mRNAs [58]. miRNAs are ubiquitously expressed, 
and regulate in a number of cellular processes in worms, flies, fish, frogs, plants and mam-
mals [60]. Over 6000 miRNAs have been discovered across all species, using molecular 
cloning and bioinformatics prediction [61]. Although the role of majority of miRNAs re-
main unclear, experimental data on a few of them show that they are involved in embryonal 
stem cell development, fat metabolism, neuronal differentiation, and cancer development 
[62, 63, 64, 65]. 
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5.2.1 Discovery of miRNA 
The first miRNA was discovered by the Ambros and Ruvkun laboratories in 1993, 
when researchers studied heterochronic gene /m-4-mediated temporal regulation of another 
heterochronic gene lin-14 in C. elegans [66, 67]. It has been shown that a 22 nucleotide 
small RNA encoded in lin-4 has multiple imperfect complimentary sites in the 3' UTR 
region of lin-14 mRNA [66, 67]. This finding suggests that lin-4 regulates the protein 
levels of lin-14 by binding to the 3' UTR region of the corresponding mRNA. As lin-4's 
homologs are not found in other species, this unique RNA based regulatory mechanism was 
thought to be present only in C. elegans. Things did not change until researchers discovered 
another heterochronic gene let-7 which has homologs in other species including human 
and drosophila. Similar to lin-4, let-7 encodes a 22 nucleotide regulatory small RNA [68]. 
This small RNA interacts with the 3' UTR of lin-41, and regulates gene expression of 
lin-41 [68]. The identification of heterochronic gene let-7 in C. elegans and other species 
revealed a new class of RNA molecules performing regulation of gene expression. This 
new class of small RNAs are then referred as microRNAs, abbreviated miRNAs, as several 
novel small RNAs with similar regulatory roles were identified [69, 70, 71]. 
5.2.2 Biogenesis of miRNA 
miRNA is made from precursor miRNA (pre-miRNA), which in turn is the product 
of a miRNA primary transcript (pri-miRNA) (Figure 5.1). pri-miRNAs are transcribed 
from the genome, and then processed to the 60-70 nucleotide pre-miRNA in the nucleus. 
The former process is brought about by RNA polymerase II [72], and the latter process is 
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promoted by the microprocessor complex consist of the nuclease Drosha and the double-
stranded RNA binding protein Pasha [73]. The pre-miRNA is processed to the mature 
22 nucleotide miRNA:miRNA* duplex by another Rnase III enzyme, Dicer. The mature 
miRNA is then released and incorporated into RNA-induced silencing complex (RISC), 
a ribonucleoprotein complex, whereas the miRNA* strand is typically degraded [74, 75]. 
The preference of the mature miRNA over the passenger strand by RISC may be partly 
due to the differences in the thermodynamic stability between the two strands [74]. The 
less thermodynamically stable 5' end of the mature miRNA renders it more unstable, and 
hence more favorable by the RISC. 
5.2.3 Regulatory mechanism 
MicroRNAs guide the RISC to regulate gene expression by either of two mechanisms: 
mRNA cleavage or translational repression. The choice of regulatory mechanisms is widely 
believed to be determined by the degree of complementarity of the miRNA with a certain 
region of its mRNA target. If the miRNA 22 nucleotides perfectly or near-perfectly match 
the mRNA sequence, the target mRNA can be cleaved and degraded; otherwise, its trans-
lation is repressed. 
An endonuclease called Argonaute 2 is required for site-specific cleavage of the target. 
This protein contains a PAZ and a PIWI domain, which are characteristic of the proteins 
of the Argonaute family and the Dicer family. The human Argonaute family contains four 
Argonaute proteins, Argonaute 1-4 (Ago 1-4). Though all of four proteins bind to miRNAs 
with similar affinities, it is only AG02 that displays endonuclease activity [76]. Structural 
data of AG02 revealed that its PIWI domain has a strikingly similarity to Rnase H type 
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Figure 5.1: miRNA biogenesis process (from WIKI). 
enzymes. This unique Rnase H-like PIWI domain is a key factor that is responsible for the 
endonuclease and site specific cleavage activity of AG02. One mRNA cleavage case has 
been reported in animal [77]. 
Most animal miRNAs performs translational repression rather than cleavage on their 
mRNA targets due to the imperfect base-pairings between them and their targets. In the 
translational repression mode, mRNAs are not degraded of target mRNAs but can be desta-
bilized as a result of deadenylation and subsequent decapping. The mechanism of trans-
lational repression by miRNA remains elusive. Controversy rises over the step at which 
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miRNAs block translation. There is evidence for translational initiation block by miRNA, 
whereas other studies suggest that miRNA blocks the elongation of transcripts [78, 79], 
Another issue is the role of processing bodies (P-bodies). P-bodies are cytoplasmic foci 
where ribosomal components do not exist and mRNAs can stay without being translated. 
Some researchers proposed that translational repression is mediated by the interaction be-
tween proteins in P-bodies and Argonaute proteins bound to miRNAs and their target mR-
NAs [80]. However, other argued that P-bodies may serve as temporary storage sites of 
translationally repressed mRNAs [81]. 
5.2.4 miRNA and disease 
miRNAs play an important role in regulation of gene expression. Dysregulation of 
miRNA function, therefore, can lead to deleterious effects. Absence of mature miRNAs 
is lethal in animals [82, 83]. In C. elegans, mutation of miRNA-producing dicer-1 leads 
to defects in germ-line development [84]. In Drosophila, depletion of Loquacious, the 
partner of Dicer-1, is responsible for female sterility [82]. In mammals, misexpression of 
miRNAs leads to deleterious biological consequences. Overexpression of the pancreatic 
islet-specific miR-375 suppressed glucose-induced insulin secretion. The deletion of its 
target, myotrophin, produce the same effect [85]. Conversely, inhibition of endogenous 
miR-375 function increases myotrophin levels and enhances insulin secretion, which indi-
cates that miR-375 is an inhibitor of glucose-stimulated insulin secretion. 
miRNAs are also associated with diseases in human. One example is the neuropsychi-
atric disorder Tourette's syndrome (TS) caused by the mutation in the 3' UTR of SLITRK1 
[86]. A GU base pair is replaced by AU pairing, which results in stronger regulation by the 
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miRNA. miRNAs may serve as tumor suppressors, which is implied by the loss of miRNA 
in cancer tissue. Chromosome region 13ql4, location of miR-15a and miR-16-1 genes, is 
deleted in most of chronic lymphocytic leukemia cases [87]. Those two miRNAs target 
the antiapoptotic gene Bcl2, which indicates that depletion of miR-15a and miR-16-1 may 
lead to the inhibition of apoptosis and produce malignancies [88]. miRNAs can also be 
potential oncogenes. The miR17-92 locus 12q31 is overexpressed in some tumors [65]. 
Amplification of this cluster in a mouse model of human B cell lymphoma accelerated the 
formation of c-Myc-induced tumor [65]. 
5.3 microRNA targeting of genes encoding extremely vul-
nerable proteins 
5.3.1 Target Identification 
The first miRNA targets were identified from genetic interaction data in Caenorbabditis 
elegans. The mutation of heterochronic mRNA lin-14 suppresses the phenotype caused by 
the mutation of miNRA lin-4. This fact led to the identification of sequence complemen-
tarity between the 3' UTR of lin-14 and the 5' portion of lin-4 (Figure 5.2). Despite its 
power, the genetic approach can identify only those targets whose overexpression results 
in the miRNA mutant phenotypes. There are few examples of this type. It remains unclear 
whether this sort of relationship is a general rule. Subsequently, the miRNA-target inter-
actions were elucidated by the miRNA-target sites mutation and miRNA misexpression 
experiments [89, 90, 91]. These studies focused on the significance of pairing to the seed 
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region located on the 5' end of the miRNA. The target sites on mRNAs can be grouped into 
two broad classes [92] : (a) 5' dominant sites base pairing perfectly with the miRNA seed 
region, and (b) 3' compensatory sites, with insufficient support from 5' pairing to miRNAs' 
3' region. 
Iin-U 3'UTR 
lin-U 5' UUCUAC-CUCAGGGAAC 3' 
lin-4 3' GAGGUG GtiBBSOBBDG 5' 
U U A S 
A C 
cuc 
Bushati N, Cohen SM. 2007. 
Annu. Rev. CellDev. Biol. 23:175-205 
Figure 5.2: The miRNAs lin-4 and let-7 repress gene expression of their targets through 
imperfect base-pairing with the target 3UTRs [92]. 
5.3.2 Computational target prediction 
Computational approach to the miRNA targets identification has been ongoing ever 
since the discovery of the first miRNA. Identification of hundreds of miRNAs in a variety 
of species and relatively small sets of targets pointed at the urgent need for accurate and 
efficient target prediction. 
The characteristics of miRNAs give arise to some specific problems and difficulties 
that hinder accurate target prediction. First, miRNAs have only 22 nucleotides, and do 
not exhibit perfect complementarity to the 3' UTRs of their target transcripts. This char-
acteristic makes it inapproriate to implement standard sequence analysis techniques that 
were designed for searching long sequence match. Second, the location, extent or splice-
variation of 3' UTRs are not known for mammals. In human, there are roughly 30% of 
lin-41 3'UTR — 100 nl 
— lin-4 
- let-7 
GUU A \ 
lin-41 5' UUAUACAACC COACOJCA 3' 
let-7 3' GAUAUGUUGG (SfflBaSiSU 5' 
AU 
5 
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genes whose exact extent of the 3' UTR can not be delineated. Third, many target pre-
diction approaches employ conservation of UTRs across species as a key filter for target 
detection, which leads to failure of identification of unconsented targets. For most mam-
malian miRNA, their targets' potential binding sites are conserved in orthologous URTs in 
multiple species. However, there exist classes of relatively recently evolved miRNAs (e.g. 
miR-430 in Zebrafish), whose targets do not share significant sequence similarity [93]. 
The computational target prediction methods developed so far fall into several cate-
gories. Their basic idea is to search sequence complementarity or favorable miRNA:target 
duplex thermodynamics. Most methods improve results by applying filters such as con-
servation of binding site and the presence of multiple sites. Many methods also require 
precise complementarity between the seed region of miRNAs and their target to further re-
duce false positives. After these filtering steps, a significance score is typically calculated 
for each potential target. 
One of the most cited algorithms is TargetScan [91]. Firstly, it detects targets by exam-
ining their complementarity to the seed region of a miRNA. Only those perfectly match are 
considered for further analysis. The method then analyzes the extent of complementarity 
outside the seed region. Unlike many other algorithms, which tend to find all potential tar-
gets and then iteratively filter them, TargetScan seeks to eliminate false-positives as many 
as possible in the early stage. Groups of orthologous sequences are also used as input 
to filter out unconsented sites early on. The initial analysis using TargetScan predicted 
miRNA targets in Humans and performed conservation analysis using the Mouse, Rat and 
Fish genomes [91]. Shuffled sequences were then used to estimate a false-positive rate of 
between 22-31%. A very large scale and detailed validation of predicted targets found that 
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TargetScan not only predicted known miRNA binding sites but also novel sites [91]. Com-
pared to other algorithms, TargetScan tends to reduce more false-positives, and is hence a 
good candidate for large-scale prediction. However, it probably misses those targets that do 
not pair perfectly in the seed regions or that are conserved poorly. A simpler version of Tar-
getScan, TargetScanS, was developed later and exhibited higher target prediction fidelity 
[94]. 
5.3.3 Target prediction results 
To obtain statistics on miRNA targeting, we identified putative target sites in the 3' 
UTRs (untranslated regions) of 17444 genes for 162 conserved miRNA families by using 
TargetScanS (version 4.0) [94]. 7,927 genes (45.4%) are predicted to contain at least one 
miRNA target site (Additional file 6), while 87 out of 105 (82.9%) extremely vulnerable 
genes are predicted to be targeted genes. Thus, human genes containing extremely vul-
nerable regions are more frequently targeted by miRNA (P « 1.31JC10~5, binomial test). 
In regards to miRNA regulation complexity, the mean number of miRNA target sites for 
human genes is 2.66 and the median is 0, while the mean number for extremely vulnerable 
genes is 6.01 and the median is 5. This significant difference (P < 10~16, Wilcox rank 
test) strongly suggests that the deviation of extremely vulnerable genes from the (r; — v)-
correlation, with expression correlation evaluated at the level of mRNA expression, can be 
explained by a post-transcriptional miRNA regulation. This type of regulation influences 
the final protein expression level. In a broad sense, this analysis highlights the connection 
between protein structure and gene regulation: extremely vulnerable genes require tight 
control at the post-transcriptional level. 
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5.4 Primitive post-transcriptional regulation of genes en-
coding extremely vulnerable proteins in yeast 
All outlier interactions in the human (TJ — v)-correlation involve genes with extreme 
vulnerability. When the same criterion for extreme vulnerability is applied to scan the 
yeast genome, 85 genes (Table 5.2) are identified whose ORFs contain the five confirmed 
prion proteins for this organism [54, 53, 55, 95]: PSI+ (SUP35), NU+ (NEW1), PIN+ 
(RNQ1), URE3 (URE2) and SWI+ (SWI1). Prions are originally found to be involved in 
mammalian neurodegenerative diseases where the aggregation of misfolded prion proteins 
causes neurodegenerative disorders. The prion concept was expanded to yeast to explain 
the unusual non-Mendelian behavior of some yeast genetic elements. The fact that five 
yeast proteins are identified to be extremely vulnerable indicates a relation between struc-
tural vulnerability of the soluble fold and aggregation propensity. 
5.4.1 Prion diseases 
Prions are infectious agents that are responsible for a variety of mammalian neurode-
generative diseases generally referred to as transmissible spongiform encephalopathies 
(TSE) or prion-diseases [96, 97, 98]. These diseases include: scrapie in sheep; bovine 
spongiform encephalopathy (also called "mad cow" disease) in cattle; chronic wasting 
disease (CWD) in deer and elk; Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-
Scheinker syndrome and kuru in human. Although the clinical, epidemiological, and neu-
ropathological features of these diseases are very different, they all involve modification 
of the prion protein (PrP), a host encoded protein predominantly expressed in the central 
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nervous system of the mammals [99]. Prion diseases cause neurodegenerative disorders 
that are sporadic, inherited and transmissible degenerative [97, 98]. 
5.4.2 Prion protein structure 
The prion protein is a 253-residue protein encoded by the gene Prnp, which consists 
of a signal peptide for secretion, five octapeptide repeats near the ends of sequence, two 
glycosylation sites, and one disulfide bridge [100]. It is expressed in most tissues, but pre-
dominantly in neuronal tissues. The prion protein has two isoforms: the normal cellular 
prion protein PrPc, rich in a-helical conformation, is soluble and protease-sensitive; the 
disease-associated misfolded prion protein PrPSc, rich in j3-sheet conformation, is insolu-
ble and mostly protease-resistant. 
PrP0 consists of an unordered N-terminal fragment and a globular C-terminal domain. 
The N-terminal domain, the segment for residue 1-128, is characterized by the octapeptide 
repeats, while the C-terminal is made of three a-helices and two small b-strand regions. 
Despite a number of amino acid differences, the 3D structure of PrP0 is highly conserved 
across several species of mammals such as human, mouse, cattle, sheep, and so on [101]. 
Although the structure of /VP5c has not been fully understood, experimental data ob-
tained by using X-ray and other biophysical techniques and computational modelling of 
small peptide fragments have provided insights into the structural rearrangement during 
prpSc formation [102, 103]. The structure transformation mostly involves the conversion 
of a-helices into j3-sheets in the globular C-terminal domain of the protein. The current 
models for PrPSc structure represents the antiparallel j3 -sheets conformation, which be-
come stabilized upon oligomerization with other PrPSc proteins (Figure 5.3). 
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Figure 5.3: Two conformations of prion domain. Prion in normal condition PrPc is dis-
played on the left, and its model of disease-related structure PrPSc is on the right (from 
Fred Cohen Laboratory, UCSF). [92]. 
5.4.3 The prion hypothesis 
The nature of the transmissible agent of TSE has been extensively studied [104]. Ini-
tially, the agent was thought to be a slow virus, because the incubation period between the 
time of exposure to the pathogen and the onset of symptoms is unusually long compared 
to other virus diseases. However, further research has shown that the agent is not likely 
to a virus. The minimum molecular weight of the agent to maintain infectivity was much 
smaller than a virus or any other known type of infectious agent [105]. The normal treat-
ments, which destroy nucleic acids, could not kill the infectious agents. Furthermore, the 
attempt to find a virus associated with the disease have been unsuccessful over the past 
30 years [97]. These and other results led Griffith to propose the "protein-only" hypothe-
sis. This hypothesis stated that the disease agent was a protein that was able to replicate 
itself in the body [106]. It gains great support from the successful isolation of a protease-
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resistant and misfolded protein from the infectious material by Stanley Prusiner's group in 
1982 [107]. This protein was named as "prion", derived from proteinaceous and infectious 
[107]. 
There is a lot of evidence which supports the prion hypothesis. Many cases of the evi-
dence were contributed by Prusiner's group. They have shown that the concentration of the 
protein was proportional to the infectivity titer [108]. Infectivity was reduced by agents, 
whose structures had been destroyed, as well as anti-PrP antibodies. In addition, infectivity 
was shown to be retained in highly purified PrPSc environment without other components. 
Another important evidence from Prusiner's group is the finding that mutation of PrP gene 
is linked to other cases of TSE. This result indicates that the genetic disease can be prop-
agated in an infectious way. There are also supports from other groups. One particular 
strong support came from Charles Weissmann's group, who showed that the PrP-deleted 
mice were resistant to scrapie infection. There were no signs of scrapie nor propagation 
of the infectious agent in those mice. These and other results provide compelling evidence 
for the prion hypothesis and almost settle the debate over the nature of the infectious agent. 
The prion protein is the only component necessary to carry the infectivity. 
5.4.4 Yeast prions 
The prion concept was expanded by Reed Wickner in 1994, to explain the unusual non-
Mendelian transmission of two yeast genetic elements termed [URE3] and [ PSI+] [109]. 
Those two traits were discovered 40 years ago, and could not be attributed to known non-
Mendelian elements, like viruses, episomes or mitochondrial genes. Wickner proposed 
that [URE3] and [PSI+] are the prion forms of the Ure2 and Sup35 proteins respectively. 
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Ure2p plays an important role in the cellular response to the nitrogen source, and Sup35p 
is involved in translation termination [110, 111]. Aggregation of these two proteins leads 
to the loss of function and produces prion phenotypes. Take for example Sup35p, which 
is a component of the translation termination complex. The protein aggregation occurs 
spontaneously at low frequency, and then recruits all normal Sup35p molecules into the 
prion state [112]. Figre 5.4 shows the mechanism of loss-of-function as a result of Sup35p 
aggregation. The prion state is passed on to the daughter cell when yeast divides. Since 
Wickner's proposal in 1994, extensive studies have provided strong support for the prion 
hypothesis in yeast [113, 114]. In addition, there are several other proteins in yeast and 
other fungi were found to exhibit the prion phenomenon [95, 113]. 
Like prions of mammals, Yeast prions transmit protein structural information in the 
absence of nucleic acid. They are all based upon the ability to self-replicate on their own. 
However, there are several important differences between two kinds of prions. In mam-
mals, prions spread from cell to cell, whereas, in yeast, prions are transferred from mother 
cells to their daughters. Yeast prions do not kill the host cells like mammalian prions. They 
produce new metabolic phenotypes. Thus, yeast prions act as heritable determinants of 
phenotype. Although the research studies on yeast prions began much later, remarkable 
progress has been achieved and made a great contribution to understand the underlying 
biology of prions. One important progress comes from studies by Weissmann's group. The 
in vitro converted purified Sup35 prion domain was introduced to the cytoplasm of living 
yeast using a liposome transformation protocol. [PSI+] prion appeared in 1 to 2% of trans-
formed cells [116]. Another similar studies showed that the introduction of fibrils made 
in vitro from renatured recombinant HET-s to the mycelia of P. anserine induced efficient 
63 
a renta l _ __ 
.,-.. ^^ ^ *«». ..-^ J- i / 
» *£>£>£>£>£>£« * ^ • • - " J ' - 1 
•> 
I- auh"jl t«"n« ij{ tm o' i n'uiri w -JL rnrr 
br'i • 
^ _ . . I ' l j r - j . i l ' * * • e ! i T , C " 
JP" * ' , , - , STOPJ (- ^ ^ 
si bosome 
•A 035 
b j | )4 i 
R .id-lr/••,•'• . t . | : • ! ) 
Figure 5.4: Sup35 protein aggregation results in a loss-of-function. a, The normal Sup35 
protein functions as a translation terminator. It interacts with Sup45, and causes 'read-
through' of stop codons. b, In [PSI+] cells, the misfolded Sup35 protein forms aggregates 
and fails to interact properly with the termination complex. As a result, stop codons are 
sometimes missed, producing increased amounts of proteins [115]. 
formation of the [Het-s] prions [117]. De novo generation of infectivity was demonstrated 
by introducing amyloid fibrils incubated with yeast-derived infectious aggregates into un-
infected yeast hosts [118]. The fact that the amyloid fibres nucleated in vitro propagate the 
prion phenotype implies that the heritable information of distinct prion strains is based on 
the folding patterns of the same prion protein. 
A common characteristic between mammalian and yeast prions is that the formation 
of j3-sheet-rich aggregates that resemble amyloid fibrils. Protein aggregation is not only 
a typical characteristic of prions, but also a key step for prion propagation. For the five 
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know yeast prion proteins, Sup35, Ure2, Rnql, Newl and S.wil, aggregation is driven by 
their Gln/Asn-rich domains. However, only Gln/Asn-richness is not sufficient to induce 
protein aggregation. Gln/Asn-rich domains of other proteins have been appended to MC 
(the middle and C-terminal prion domain) of Sup35. Those domains from confirmed prions 
such as Rnql and Newl could replace the N terminal prion domain of Sup35 and form 
a [P5/+]-like prion, whereas the domain from Panl could not [56, 119, 120]. Further 
research on prion domains of Sup35, Rnql and Newl showed that those prion domains 
have a positive bias for tyrosine, glycine and serine, and a negative bias for glutamate, 
aspartate, arginine [121]. 
Another important feature of yeast prions is their oligopeptide repeat sequences. There 
are five imperfect repeats (R1-R5) and one partial repeat (R6) in residues 41-97 of Sup35 
that also compose the only sequence section similar to mammalian prion protein PrP. Dele-
tion of two or more oligopeptide repeats in Sup35 destroy [PSI+], whereas two additional 
copies of R2 increase dramatically the spontaneous appearance of prion state [122]. It 
has been suggested that the repeats might facilitate the correct alignment of intermolecular 
contacts between molecules [54]. Consistently, appending of a polyglutamine tract to the 
MC of Sup35, does not support [PSI+], but addition of Sup35 repeats induces the prion for-
mation , although proteins aggregates in both cases [123]. Their result indicates amyloid 
fibres are not necessarily prions. 
Prion aggregation results in a loss-of-function of native proteins. For instance, Sup35 
plays an important role in translation termination, and formation of [PSI+] produces termination-
defective phenotypes [124, 125]. [PSI+] causes ribosomes to read through some nature 
occurring stop codons. It seems that [P5/+]-mediated disruption to translation-termination 
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could not lead to beneficial consequences. However, the conservation of Sup35 prion do-
main and its ability to switch to [PSI+] state over several hundred million years implies that 
[PSI+] might confer some advantages over the normal Sup35 protein (Figure 5.5 [126]). 
An assessment of the fitness of [PSI+] cells and [psi-] cells in 150 diverse growth 
conditions has provided important support to the hypothesis that [PSI+] state could be 
beneficial [127]. The fitness of [PSI+] cells increases in 25% of conditions in at least 
one genetic background, and decreases in another 25% of conditions [127]. Furthermore, 
[PSI+] could induce profound alterations in colony morphology or stress tolerance [127, 
128]. A variety of beneficial and heritable phenotypes arisen from subtle [PSI+] alterations 
in translation-termination fidelity [127]. 
Studies on beneficial roles of prions have also been extended to other prions [129, 130]. 
The function of [RNQ+], [URE3] and [PIN+] is not well characterized. However, they can 
all induce the [PSI+] formation [129, 130]. 
Prions are epigenetic, because their phenotypes can be inherited without modification 
of the genome. This characteristics provide a survive advantage in the fluctuation envi-
ronments. Prions also serve as possible evolutionary capacitors and have essential roles in 
long-term memory formation [126]. 
5.4.5 Prion aggregation as a means of regulating gene expression of 
yeast extremely vulnerable proteins? 
Extremely vulnerable proteins are subject to significant levels of post-transcriptional 
regulation. In human, this extra regulation is achieved through extensive miRNA targeting 
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Figure 5.5: [PSI+] may confer some advantages over the normal Sup35 protein [126]. a, 
Transition between [PSI+] and [psi~] states. [PSI+] individuals appear spontaneously in a 
population of [psi~] cells, and become dominant in some particular environment (condition 
B). When the situation changes (condition A), [psi~] individuals thrive and [psi~] cells 
die gradually. The transition between two states enables yeast cells to survive in some 
extreme circumstances, b, Expression of the usually silent genetic information as a result 
of readthrough of stop codons. (1) The expression of pseudogenes that are mutated in silent 
state may produce new functions. (2) C-terminal extensions on polypeptides perhaps alter 
protein function. (3) Two open reading frames are merged to yield new hybrid proteins. 
(4) Nonsense-mediated decay pathways are repressed to stabilize mRNAs. (5) Non-stop 
decay destabilizes mRNAs and alters the expression levels of proteisn. 
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of genes encoding extremely vulnerable proteins. In budding yeast, on the other hand, our 
results indicate that such a regulation is likely achieved through sequestration of the ex-
tremely vulnerable proteins into aggregated states. All five experimentally verified prions 
in budding yeast are found to be in the 85 extremely vulnerable protein list (Table 5.2). 
Unlike mammalian prions, yeast prions are potentially beneficial to the survival of cells 
in some specific circumstances [127]. Prion aggregation in yeast may provide some se-
lective advantages [126]. The inclusion of five prion proteins in the extremely vulnerable 
proteins implies that if the extremely vulnerable proteins are themselves translational regu-
lators, the sequestration to aggregated states may directly lead to epigenetic consequences 
and phenotypic polymorphism [127,128]. Whether prion aggregation serves as a potential 
mechanism of gene expression regulation in yeast is an issue worthy of investigation. The 
experimental verification of other 80 extremely vulnerable proteins as prions can provide 
strong support to this hypothesis. 
Table 5.2: List of extremely vulnerable proteins in yeast 
SwissProt ID 
P05453 
P23202 
P25367 
Q08972 
P09547 
P10591 
P25339 
P40467 
P38216 
P19158 
P40485 
Protein Name 
Eukaryotic peptide chain release factor GTP-binding subunit (ERF2) 
Protein URE2 
[PIN+] prion protein RNQ1 
[NU+] prion formation protein 1 
Transcription regulatory protein SWI1 
Heat shock protein SSA1 
Protein PUF4 
Probable transcriptional regulatory protein YIL130W 
Uncharacterized protein YBR016W 
Inhibitory regulator protein IRA2 
Phosphatidylinositol 4,5-bisphosphate-binding protein SLM1 
Continued on next page 
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Table 5.2: List of extremely vulnerable proteins in yeast 
SwissProt ID 
P32505 
P34761 
P25299 
P25294 
P38042 
P32334 
P22470 
P29295 
P32521 
Q12489 
P50109 
Q06449 
PI1938 
P39105 
P19659 
P38741 
P47033 
P40956 
Q05672 
P53281 
P32629 
P22082 
Q08601 
P33417 
P43582 
Q08954 
Q12224 
Q12221 
P18899 
P25644 
Q03761 
Protein Name 
Nuclear polyadenylated RNA-binding protein NAB2 
Protein WHI3 
mRNA 3'-end-processing protein RNA15 
Protein SIS 1 
Anaphase-promoting complex subunit CDC27 
Protein MSB2 
Protein SAN1 
Casein kinase I homolog HRR25 
Protein PAN1 
Uncharacterized protein YDL012C 
Protein PSP2 
[PSI+] inducibility protein 3 
DNA-binding protein RAP1 
Lysophospholipase 1 precursor 
RNA polymerase II mediator complex subunit 15 
Probable RNA-binding protein YHL024W 
Protein PRY3 
Protein GTS1 
RNA-binding suppressor of PAS kinase protein 1 
LAS17-interacting protein 1 
Mannan polymerase II complex ANP1 subunit 
Transcription regulatory protein SNF2 
Metacaspase-1 precursor 
Intrastrand cross-link recognition protein 
WW domain-containing protein YFL010C 
Uncharacterized protein YPL199C 
Transcription factor RLM1 
Protein PUF2 
Stress protein DDR48 
Topoisomerase II-associated protein PAT1 
Transcription initiation factor TFIID subunit 12 
Continued on next page 
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Table 5.2: List of extremely vulnerable proteins in yeast 
SwissProt ID 
P11746 
P14680 
Q03482 
Q02792 
Q02799 
P38429 
Q05854 
Q04951 
P18480 
Q02630 
P80667 
Q12361 
P27654 
P38856 
Q03825 
P53894 
P34756 
Q08732 
P38266 
P53214 
P34217 
Q07800 
P38248 
P40552 
P10863 
Q45U13 
P31384 
P38129 
P14922 
P35732 
P19097 
Protein Name 
Pheromone receptor transcription factor 
Dual specificity protein kinase YAK1 
Uncharacterized protein YDR210W 
5'-3' exoribonuclease 2 
Zinc finger protein LEE1 
Transcriptional regulatory protein SAP30 
Probable transcriptional regulatory protein YLR278C 
Probable family 17 glucosidase SCW10 precursor 
Transcription regulatory protein SNF5 
Nucleoporin NUP116/NSP116 
Peroxisomal membrane protein PAS20 
G protein-coupled receptor GPR1 
Temperature shock-inducible protein 1 precursor 
Hypothetical 71.7 kDa protein in REC104-SOL3 intergenic region 
Hypothetical 85.0 kDa protein in HLJ1-SMP2 intergenic region 
Serine/threonine-protein kinase CBK1 
l-phosphatidylinositol-3-phosphate 5-kinase FAB1 
Serine/threonine-protein kinase HRK1 
Uncharacterized protein YBR108W 
Hypothetical 57.5 kDa protein in VMA7-RPS25A intergenic region 
RNA-binding protein PIN4 
Phosphatase PSR1 
Extracellular matrix protein 33 precursor 
Cell wall protein TIR3 precursor 
Cold shock-induced protein TIR1 precursor 
Yill30wp 
Glucose-repressible alcohol dehydrogenase transcriptional effector 
Transcription initiation factor TFIID subunit 5 
Glucose repression mediator protein CYC8 
Uncharacterized protein YKL054C 
Fatty acid synthase subunit alpha 
Continued on next page 
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SwissProt ID 
P54785 
P53438 
P53334 
P40002 
Q08906 
P04050 
Q05785 
P39743 
P38180 
P32583 
P41910 
P38996 
Protein Name 
Transcriptional activator/repressor MOT3 
Protein SOK2 
Probable family 17 glucosidase SCW4 precursor 
Uncharacterized protein YEL007W 
Facilitator of iron transport 2 precursor 
DNA-directed RNA polymerase II largest subunit 
Epsin-2 
Reduced viability upon starvation protein 167 
Uncharacterized protein YBL081W 
Suppressor protein SRP40 
Repressor of RNA polymerase III transcription MAF1 
Nuclear polyadenylated RNA-binding protein 3 
5.5 Summary 
The correlation between gene co-expression and protein structure vulnerability is weaker 
in human than the correlation in yeast. The outliers in human correlation involve ex-
tremely vulnerable proteins, which are more needy for protection from their binding part-
ners. Genes encoding extremely vulnerable proteins are dosage sensitive, and hence re-
quire tighter post-transcriptional control. As shown in microRNA target prediction results, 
genes encoding extremely vulnerable proteins are more frequently targeted by microRNAs 
in human. In budding yeast, there are no signs of RNA interference. However, yeast ex-
tremely vulnerable protein list contains five conformed prions. Prion protein aggregation 
is potentially beneficial for cell survival, as it can produce diverse phenotypes in different 
71 
environments. Post-transcriptional regulation of genes encoding extremely vulnerable pro-
teins is proposed to be achieved through sequestration of the extremely vulnerable proteins 
into aggregated states. Experimental verification of those extremely vulnerable proteins as 
prions could further provide support to this theory. 
Chapter 6 
Protein structure vulnerability decreases 
gene duplicability 
Chapter 4 tests the prediction that protein structure vulnerability provides molecular 
basis for gene dosage sensitivity, by examining the gene co-expression and structure vul-
nerability of interacting proteins. This prediction can also be verified by examining the 
effect of protein structure vulnerability on gene duplication. Protein structure vulnerability 
quantifies the extent to which protein structure relies on binding partners to maintain its 
integrity. Highly vulnerable proteins are needy for association with binding partners. Ac-
cording to our prediction, duplicates of genes encoding highly vulnerable proteins should 
be more likely to cause dosage imbalance and hence be less frequently to be retained in 
evolution. This chapter examines this deduction by analyzing the relationship between 
protein structure vulnerability and gene duplicability. 
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6.1 A negative effect of protein structure vulnerability on 
gene duplication 
Gene duplication is one of the key factors producing new genetic variants [131, 132]. 
Recently, the evolutionary forces influencing gene duplicability have received intense in-
terest. In particular, much effort has been devoted to explain gene duplication patterns 
at the genomic level using the gene dosage balance theory described in Chapter 2 [23]. 
According to the dosage balance hypothesis, dosage sensitive genes are less likely to be 
retained in evolution, and have fewer paralogs than dosage insensitive genes. In Chapter 4, 
we show that protein structure vulnerability quantifies the level of gene dosage sensitivity. 
As a result, we predict that the probability of retention of gene duplicates in evolution (i. 
e., gene duplicability) depends on the structure vulnerability of the protein encoded by the 
gene. 
We collaborated with Li group to test this prediction [133]. We compiled a non-
redundant set of proteins with PDB-reported structure in six organisms: E. Coli, yeast, 
worm, fly, human and thale cress. Then we determined both the structure vulnerability 
(or called as under-wrapping) and duplicability for each protein. Structure vulnerability 
was calculated as shown in chapter 3. Gene duplicability is quantified by the number of 
members in a gene family (i.e., the gene family size). E. Coli gene family annotation was 
obtained from Genome and Proteome Database, while family annotations for other five 
species were extracted from Ensembl Database [134]. We found that the under-wrapping 
decreases with increasing gene duplicability in all six organisms (Figure 6.1 and 6.2). 
Genes with particular biological functions have been shown to duplicate more fre-
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Figure 6.1: Anti-correlations between under-wrapping and gene duplicability in E. coli 
(A), in yeast (B) and, in human (C), and in slopes in six organisms (D). Gene duplicability 
is defined as the gene family size. The mean level of wrapping is calculated by averaging 
over all genes with the same duplicability. 
quently in evolutionary history [135, 136]. We then investigated the potential influences 
of functional bias on our results, by comparing the under-wrapping levels between yeast 
singletons and duplicates for different functional categories. It turned out that singletons 
are consistently more under-wrapped than duplicates for each functional category. This 
result shows that the effect of the protein under-wrapping on gene duplicability does not 
depend on the gene function (Figure 6.3). 
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Figure 6.2: Anti-correlations between under-wrapping and gene duplicability in worm (A), 
fly (B), and thale cress (C). 
6.2 Protein structure vulnerability dependency of gene du-
plication varies across species 
Anti-correlations between protein under-wrapping and gene duplicability in six organ-
isms strongly support our prediction that gene duplication is dependent on the level of pro-
tein under-wrapping. For all species, the decreasing trend is evident for genes with family 
size less than 5 and become less obvious at higher duplicability. However, the extent of 
correlation between two quantities varies across six organisms. The correlation differences 
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Figure 6.3: Yeast singletons are more under-wrapped than duplicates in all the functional 
categories. 
can be seen more clearly using a linear regression between protein under-wrapping and 
gene duplicability in six organisms. As shown in Figure 6. ID, the effect of protein under-
wrapping on gene duplicability decreases with increasing organismal complexity, that is, 
E. Coli > yeast > worm > fly ~ human ~ thale cress. It suggests that dosage imbalance 
may play a less important role in complex organisms. To investigate the correlation dif-
ferences between organisms, we studied the under-wrapping distributions in E. coli, yeast 
and human. The results are shown in Figure 6.4. The under-wrapping of human proteins 
is mainly distributed between 35% and 55%, while the distributions of under-wrapping of 
proteins are wider in E. Coli and yeast. It implies that more human proteins are reliant 
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on binding partners for structure integrity. The contrasting under-wrapping distributions 
provide some clue to understand the correlation difference between organisms. However, 
it still needs more investigation. 
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Figure 6.4: Distributions of percentage of families based on wrapping levels in Human (A), 
in Yeast (B), and in E. Coli (C). 
In higher eukaryotes, genes encoding highly under-wrapped proteins have more par-
alogs, suggesting that complex organisms are less sensitive to the dosage imbalance effects. 
There are several possible reasons. First, there are more efficient expression regulatory 
systems in complex organisms. As we discussed in Chapter 5, microRNAs down-regulate 
expression of dosage sensitive genes. Second, sequence divergence in higher eukaryotes 
may be more significant, which help them to avoid dosage imbalance. Third, paralogs can 
interact with each other [137]. This phenomenon may be more prevalent in higher eukary-
otes. Fourth, complex organisms generally have a smaller effective population size [138], 
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which leads to less chance of dosage imbalance. The last possible factor is the positive 
selection due to functional diversification in complex organisms [139]. 
6.3 Vulnerability-duplicability correlation differences be-
tween whole-genome duplication (WGD) and non-WGD 
duplicates 
The effect of protein under-wrapping on gene duplicability depends on the scale of du-
plication. In a whole-genome duplication (WGD) every gene in the genome is duplicated 
at the same time, while only part of the genome duplicates in a non-WGD (including indi-
vidual or segmental duplication). Therefore, duplicates of highly under-wrapped proteins 
in WGD should be less likely to result in dosage imbalance, and have more chances of sur-
viving from duplications. Focusing on the yeast proteins with only one paralog, we found 
a statistical significant difference between the under-wrapping levels in two kinds of dupli-
cation (Figure 6.5 A). Proteins surviving from WGDs have a higher under-wrapping level 
that those from non-WGDs, which implies that the dosage imbalance effect was relaxed 
for gene duplications in WGD. The gene ontology (GO) analysis found that this trend is 
present for genes from different function categories (Figure 6.5 B). 
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Figure 6.5: (A) Contrasting wrapping level distributions between WGD (Black bar) and 
Non-WGD (grey bar) duplicates. (B) Wrapping level distributions over gene functions for 
two groups. GO mapping for yeast genes is provides by a GO term analysis tool-GO term 
finder [140]. 
6.4 Summary 
Gene duplication can produce new gene copies, and hence become one of main forces 
driving genetic innovations. However, segmental duplication may lead to a dosage imbal-
ance between interacting partners. Highly vulnerable proteins, which are highly reliant on 
binding partners to maintain their structure integrity, are less likely to be duplicated during 
gene duplications. Results in this chapter provide additional support to our prediction that 
protein structure vulnerability serves as a molecular basis for the dosage imbalance effect. 
Chapter? 
Conclusions and Ramifications 
Genes are not always expressed at normal levels. Gene expression variation produces 
different phenotypes. Both under- and overexpression of genes could lead to abnormal 
phenotypes. Dosage balance theory has been proposed to explain gene dosage effects. Sto-
ichiometric imbalances in macromolecular complexes can be a source of dominant pheno-
types. Both gene deletion and overexpresion of a single subunit in a protein complex could 
be deleterious. The strength of transcriptional co-regulation of interacting pairs is expected 
to reflect dosage sensitivity. Gene dosage balance theory has been supported by several 
experimental results from Papp's group: dosage sensitive genes are at least twice more 
likely to encode proteins involved in complexes than dosage insensitive genes; compo-
nents of protein complexes counts a significant portion of the genes whose overexpression 
in wild-type cell is lethal; interacting pairs with high dosage sensitivity are much more 
co-expressed than the others. 
This work studies gene dosage sensitivity by examining the extent of protein structure 
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vulnerability. Soluble protein structure may be more or less vulnerable to water attack de-
pending on their packing quality. We quantify the structure vulnerability by determining 
the extent of solvent exposure of backbone hydrogen bonds. Within this scheme, local 
weaknesses in the protein structure may become protected upon complexation, as exposed 
backbone hydrogen bonds become exogenously dehydrated. Vulnerable structures are thus 
quantitatively reliant on binding partnerships to maintain their integrity, suggesting that 
vulnerability may be regarded as a structure-based indicator of gene dosage sensitivity. 
This observation is validated by establishing the significance of protein vulnerability or 
structure protection as an organizing factor in temporal phases (yeast) and tissue-based 
(human) transcriptomes. Specifically, this role was established by examining the degree 
of co-expressions of a protein with its binding partners in structure-represented interac-
tions. Thus, for each Pfam-filtered binding partnership, the extent of co-expression across 
metabolic adaptation phases (yeast) or tissue types (human) was found to depend quantita-
tively on the structure vulnerability of the proteins involved. Hence, vulnerability may be 
regarded as an organizing factor encoded in the structure of gene products. 
Furthermore, as shown in this work, the tight coordination between translation reg-
ulation and gene function dictates that extremely vulnerable, and hence "highly needy", 
proteins are subject to significant levels of post-transcriptional regulation. In human, this 
extra regulation is achieved through extensive miRNA targeting of genes coding for ex-
tremely vulnerable proteins. In yeast, on the other hand, our results imply that such a 
regulation is likely achieved through sequestration of the extremely vulnerable proteins 
into aggregated states. Intriguingly, the 85 yeast genes containing extremely vulnerable 
proteins included the five confirmed yeast prions. Unlike mammalian prions, as suggested 
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by Lindquist, yeast prion protein aggregation provides phenotype plasticity and can confer 
some selective advantages. These results suggest that extremely vulnerable proteins resort-
ing to aggregation to buffer the deleterious consequences of dosage imbalance. However, 
a rigorous proof will require a structure-based integration of information drawn from the 
interactome, transcriptome and post-transcriptional regulome. 
If validated, the hypothesis that aggregation circumvents the deleterious effects of 
dosage imbalance would imply a selective advantage for yeast but this advantage may be 
significantly reduced in human, where self-templating aggregation traits are well known to 
be pathogenic. An evolutionary piece of evidence appears to support the hypothesis that 
aggregation may import a fitness advantage by mitigating dosage imbalance effects. In 
chapter 6, we established that genes coding for poorly wrapped yet structured proteins tend 
to be singletons, because the duplicates would be under severe selection pressure as they 
compete for obligatory binding partners. However, the average number of surviving par-
alogs for extremely vulnerable proteins is 3.2 in yeast and 5.1 in human. This suggests that 
the dosage imbalance brought about by gene duplication may be mitigated for extremely 
vulnerable proteins. 
Aggregation may indeed constitute a primitive post-transcriptional regulatory element 
in unicellular eukaryotes like yeast, it is kept suppressed in human by an additional layer 
of post-transcriptional regulation. This would lead us to the far-reaching hypothesis that 
self-templating aggregation is a precursor of miRNA regulation. Proving this hypothesis is 
not an easy task. Yet, this picture needs to be explored and further validated by assessing 
the biological forces associated with dosage imbalances in yeast and human. 
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